ПОЛИМЕРНЫЕ ПО СУЩЕСТВУ РЕНТГЕНОКОНТРАСТНЫЕ ПРОДУКТЫ ДЛЯ ЭМБОЛОТЕРАПИИ

... 1. Эмболотерапевтический продукт, включающий состав в форме частиц, включающий биосовместимый, биоразрушаемый полимер, и необязательно включающий его стереоизомеры, где полимер включает достаточное количество атомов галогена для придания эмболотерапевтическому продукту по существу (по природе) рентгеноконтрастности. 2. Эмболотерапевтический продукт по п.1, где указанный полимер дополнительно включает гомополимер, гетерополимер или их смесь. 3. Эмболотерапевтический продукт по п.1, где указанный полимер включает одно или более звеньев, описываемых формулой I где X=I или Br; Y1 и Y2 могут независимо = 0, 1, 2, 3 или 4; где f равно между 0 и менее 1; g равно 0-1, включительно; и f+g равно 0-1, включительно; где A представляет собой либо где R1 независимо представляет собой H или алкильную группу, содержащую от 1 до приблизительно 18 углеродных атомов и 0-5 гетероатомов, выбранных из O и N; где R3 представляет собой насыщенную или ненасыщенную, замещенную или незамещенную алкильную, арильную ...

ПОЛИМЕРЫ, НЕПРОНИЦАЕМЫЕ ДЛЯ РЕНТГЕНОВСКОГО ИЗЛУЧЕНИЯ

СОСТАВ ГЕЛЯ ДЛЯ ЛУЧЕВОЙ ТЕРАПИИ ПОД ВИЗУАЛЬНЫМ КОНТРОЛЕМ

POLYAMINOSÄUREN-METALLKOMPLEXE UND IHRE ANWENDUNG IN DIAGNOSTISCHER BILDERZEUGUNG

Imageable polymers

COMPOSITIONS CONTAINING HIGH CONCENTRATION FROM CONTRAST MEANS TO EMBOLISIERUNG OF BLUTGEFASSEN

ORGANIC ROENTGEN CONTRAST MEANS FOR MEDICAL INSTRUMENTS

NEW, SILICONE RUBBER MIXTURE SUITABLE FOR APPLICATION IN THAT ENDOVASCULAEREN AND GENERAL SURGERY AND THIS MIXTURE OF EXHIBITING HEILBEHELF

IODO CONNECTIONS, YOUR PRODUCTION AND USE AS CONTRAST MEANS FOR X-RAYING RADIOLOGY

STRICTLY ALTERNATING POLY (ALKYL OXIDE) COPOLYMERS

IODINATED POLYMERS

Radiopaque polymers for medical devices

Radiopaque polymer compositions and methods for making the compositions are provided. These radiopaque polymer compositions include polymer compositions comprising a crosslinked polymer network, the network comprising a first repeating unit derived from a monofunctional monomer and a second repeating unit derived from a multifunctional non-iodinated monomer wherein neither of the two monomers is fluorinated. Devices formed from radiopaque polymer compositions are also provided.

Polymeric treatment compositions

Polymeric compositions are described comprising a biocompatible polymer including a biodegradable linkage to a visualization agent and a non-physiological pH solution; wherein the biocompatible polymer is soluble in the non-physiological pH solution and insoluble at a physiological pH. Methods of forming the solutions and polymers are disclosed as well as methods of therapeutic use.

Implantable particles for tissue bulking and the treatment of gastroesophageal reflux disease, urinary incontinence, and skin wrinkles

Polyiodinated compounds, preparation and use thereof in x-ray radiology

IMPLANTS AND BIODEGRADABLE FIDUCIAL MARKERS

Implantable materials may be used in an iatrogenic site. Applications include radioopaque materials for fiducial marking.

EMULSION COMPRISING PARTICLES

The present invention provides emulsion compositions comprising an continuous oil phase, a discontinuous aqueous phase and a plurality of microparticles. The composition may comprise a pharmaceutical active ingredient located in the oil phase, the particulate phase or the aqueous phase. The emulsion compositions have improved stability and coherence and are useful in the treatment of tumours by embolotherapy.

LIQUID EMBOLIC COMPOSITIONS AND USES THEREOF FOR TREATING VASCULAR CONDITIONS

The present invention relates generally to polymeric compositions and uses of these compositions to treat vascular conditions. The polymeric composition may comprise a substantially stable biocompatible polymer comprising a reaction product of: a first monomer including a polymerizable moiety having a biodegradable linkage to a visualization agent having at least one aromatic ring, wherein the at least one aromatic ring includes a plurality of iodine atoms, and a second monomer including a polymerizable moiety and at least one hydroxyl group; and a non-physiological solution; wherein the substantially stable biocompatible polymer is soluble in the non-physiological solution and insoluble in a physiological solution. Also described are polymers and embolic systems.

POLYMERIC X-RAY CONTRAST COMPOSITIONS CONTAINING IODINATED POLYMERIC BEADS

Disclosed are x-ray contrast compositions for oral or retrograde examination of the gastrointestinal tract comprising a polymeric material in combination with a divalent cation capable of forming a coating on the gastrointestinal tract and iodinated polymeric, water-insoluble beads having a particle size of from about 0.01 to about 1000.mu. wherein said iodinated polymeric beads comprise a polymer containing repeating units of formula (I) wherein A is a repeating organic unit in the backbone chain of the polymer; and X is an organic moiety containing or iodinated aromatic group and a hydrophilic group, said moiety having an iodine content within the range of from about 40 to about 80 weight percent based on the molecular weight of X, in a pharmaceutically acceptable carrier.

Für X-Strahlung undurchlässiges Material und Verfahren zu dessen Herstellung.

Verfahren zur Sichtbarmachung von Körperhohlräumen bei der Röntgenographie

Procédé pour visualiser des cavités du corps à l'aide de rayons X et préparation pour la mise en oeuvre de ce procédé

Procédé pour visualiser des cavités du corps à l'aide des rayons X et préparation pour la mise en oeuvre de ce procédé

Imageable polymers

X-RAY CONTRAST AGENT

Polymères iodés, à squelette dextrane, leurs procédés de préparation et leurs applications comme produits de contraste

Polymères iodés, leurs procédés de préparation et leurs applications comme produits de contraste. L'invention a pour objet des polymères iodés comprenant un squelette constitué par un dextrane sur lequel sont greffés des groupes de formule ...

RADIOPAQUE POLYMERS

NOVEL COMPOUNDS COMPRISING IODISED OR FLUORINATED DENDRIMERIC GROUPS, METHODS FOR PREPARING SAME AND USES THEREOF

The present invention relates to compounds comprising dendrimeric groups that are heavily loaded with iodine or fluorine and optionally a functional group, the use thereof, the method for preparing same and the uses thereof, in particular as contrast agents or radioactive tracers.

Contrast Agents

The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds containing a cyanuric acid scaffolding moiety allowing for the arrangement of three iodinated phenyl groups bound thereto. The invention also relates to the use of such diagnostic compositions as contrast agents in diagnostic imaging and in particular in X-ray imaging and to contrast media containing such compounds.

IMPLANTABLE PARTICLES FOR TISSUE BULKING AND THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE, URINARY INCONTINENCE, AND SKIN WRINKLES

The invention encompasses the treatment of urinary incontinence, gastroesophageal reflux disease and the amelioration of skin wrinkles using biocompatible hydrophilic cationic microparticles and a cell adhesion promoter.

IODIERTE POLYMERE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG ALS KONTRASTMITTEL.

Röntgendichte polymerische Biomateriale

Imageable polymers

A hydrogel comprising 1,2-diol or 1,3-diol groups acetalised with a radiopaque species, the radiopaque species comprising one or more covalently bound radiopaque halogens. Preferably the radiopaque species is acetalised in the form of a cyclic acetal. The hydrogel may comprise polyvinyl alcohol (PVA). The radiopaque species may be iodine or bromine, preferably iodinated or brominated phenyl groups. The hydrogel may be in the form of a microsphere or microparticle, preferably having a radiopacity of 500HU or greater. A further aspect of the invention is a composition comprising the hydrogel with a therapeutic agent absorbed into the hydrogel matrix. A method of making the radiopaque polymer comprising reacting a polymer comprising 1,2-diol or 1,3-diol groups with a radiopaque species capable of forming a cyclic acetal under acidic conditions. A method of making radiopaque hydrogel microspheres comprising swelling a pre-formed hydrogel microsphere with 1,2-diol or 1,3-diol groups in a solvent, mixing the swollen microsphere with a solution of radiopaque species capable of forming a cyclic acetal under acidic conditions and extracting the microspheres. A method of treatment wherein the hydrogel is administered into a blood vessel to embolise the blood vessel, preferably associated with a solid tumour.

Roentgen contrast means

NEW, SILICONE RUBBER MIXTURE SUITABLE FOR APPLICATION IN THAT ENDOVASCULAEREN AND GENERAL SURGERY AND THIS MIXTURE OF EXHIBITING HEILBEHELF

NEUE, ZUR ANWENDUNG IN DER ENDOVASCULAEREN UND ALLGEMEINEN CHIRURGIE GEEIGNETE SILIKONKAUTSCHUK- MISCHUNG UND DIESE MISCHUNG AUFWEISENDER HEILBEHELF

RADIATION-PERMEABLE POLYMERE BIOLOGICAL MATERIAL

Implants and biodegradable fiducial markers

Implantable materials may be used in an iatrogenic site. Applications include radioopaque materials for fiducial marking.

Radiopaque monomers, polymers, microspheres, and methods related thereto

Radiopaque monomers, polymers, and microspheres are disclosed herein. Methods of using the radiopaque monomers, polymers, and microspheres are disclosed herein. Methods of manufacturing radiopaque monomers, polymers, and microspheres are disclosed herein.

RADIOPAQUE POLYMERS

A liquid composition comprising a polymer having pendant groups of the formula I: (I) Wherein X is either a bond or is a linking group having 1 to 8 carbons and optionally 1 to 4 heteroatoms selected from O, N and S; and n is 1 to 4.

X-RAY CONTRAST AGENT

POLYMERIC BIOMATERIALS DERIVED FROM PHENOLIC MONOMERS AND THEIR MEDICAL USES

Disclosed are new classes of diphenol compounds, derived from tyrosol or tyrosol analogues and hydroxybenzoic acid, which are useful as monomers for preparation of biocompatible polymers. Also disclosed are biocompatible polymers prepared from these monomeric diphenol compounds, including novel biodegradable and/or bioresorbable polymers of formula. These biocompatible polymers or polymer compositions with enhanced bioresorbabilty and processibility are useful in a variety of medical applications, such as in medical devices and controlled-release therapeutic compositions. The invention also provides methods for preparing these monomeric diphenol compounds and biocompatible polymers.

RADIOPAQUE SHAPE MEMORY POLYMERS FOR MEDICAL DEVICES

Radiopaque polymer compositions and methods for making the compositions are provided. These radiopaque polymer compositions include shape memory polymer compositions comprising a crosslinked polymer network, the network comprising a first repeating unit derived from a monofunctional iodinated monomer and a second repeating unit derived from a multifunctional non-iodinated monomer wherein neither of the two monomers is fluorinated. Devices formed from radiopaque polymer compositions are also provided.

RADIOPAQUE POLYMERS FOR MEDICAL DEVICES

Radiopaque polymer compositions and methods for making the compositions are provided. These radiopaque polymer compositions include polymer compositions comprising a crosslinked polymer network, the network comprising a first repeating unit derived from a monofunctional monomer and a second repeating unit derived from a multifunctional non-iodinated monomer wherein neither of the two monomers is fluorinated. Devices formed from radiopaque polymer compositions are also provided.

IMAGEABLE EMBOLIC MICROSPHERE

This invention concerns imageable, radiopaque embolic beads, which are particularly useful for monitoring embolization procedures. The beads comprise iodine containing compounds which are covalently incorporated into the polymer network of a preformed hydrogel bead. The beads are prepared by activating pre-formed hvdrogel beads towards nucleophilic attack and then covalently attaching iodinated compounds into the polymer network. The radiopaque beads may be loaded with chemotherapeutic agents and used in methods of embolizing hyperplastic tissue or solid tumors.

STRICTLY ALTERNATING POLY(ALKYLENE OXIDE ETHER) COPOLYMERS

Polyether copolymers characterized by strictly alternating poly(alkylene oxide) and aromatic diol monomeric repeating units, wherein the combination of repeating units is effective to provide the polyether wit h a hydrophilic/hydrophobic ratio at which aqueous micelle self-assembly occurs. Stable aqueous dispersions of hydrophobic drugs are al so disclosed, as well as medical implants and drug delivery devices for implantation.

STRICTLY ALTERNATING POLY(ALKYLENE OXIDE ETHER) COPOLYMERS

Polyether copolymers characterized by strictly alternating poly(alkylene oxide) and aromatic diol monomeric repeating units, wherein the combination of repeating units is effective to provide the polyether with a hydrophilic/hydrophobic ratio at which aqueous micelle self-assembly occurs. Stable aqueous dispersions of hydrophobic drugs are also disclosed, as well as medical implants and drug delivery devices for implantation.

COMPLEX METAL WITH POLIAMINOOKSIDAMI AND ITS APPLICATION FOR FORMING IMAGES DIAGNOSTICS

Radiopaque polymers for medical devices

METAL COMPLEXES OF POLYAMINOACIDES, THEIR METHOD OF PREPARATION AND THEIR USE IN DIAGNOSTIC IMAGERY

The invention relates to complexes of gadolinium having the formula (I) wherein R is a group having formula (1). These complexes are usable in the field of diagnostic imaging.

POLYMERS IODIZE, HAS SKELETON DEXTRANE, THEIR METHODS OF PREPARATION AND THEIR APPLICATIONS LIKE PRODUCTS OF CONTRAST

Polymères iodés, leurs procédés de préparation et leurs applications comme produits de contraste. L'invention a pour objet des polymères iodés comprenant un squelette constitué par un dextrane sur lequel sont greffés des groupes de formule (CF DESSIN DANS BOPI) où les groupes R sont simultanément des groupes dérivant d'amines triiodobenzémiques et des groupes dérivant d'amines aliphatiques. Iodinated polymers, their preparation processes and their applications as contrast media. The subject of the invention is iodinated polymers comprising a backbone consisting of a dextran onto which are grafted groups of formula (CF DRAWING IN BOPI) where the R groups are simultaneously groups derived from triiodobenzemic amines and groups derived from amines. aliphatic.

Imageable embolic microsphere

This invention concerns imageable, radiopaque embolic beads, which are particularly useful for monitoring embolization procedures. The beads comprise iodine containing compounds which are covalently incorporated into the polymer network of a preformed hydrogel bead. The beads are prepared by activating pre-formed hydrogel beads towards nucleophilic attack and then covalently attaching iodinated compounds into the polymer network. The radiopaque beads may be loaded with chemotherapeutic agents and used in methods of embolizing hyperplastic tissue or solid tumors.

RADIOPAQUE MONOMERS, POLYMERS, MICROSPHERES, AND METHODS RELATED THERETO

Radiopaque monomers, polymers, and microspheres are disclosed herein. Methods of using the radiopaque monomers, polymers, and microspheres are disclosed herein. Methods of manufacturing radiopaque monomers, polymers, and microspheres are disclosed herein. 120-. (canceled)24. The method of claim 21 , wherein the polymer comprises an anionic functional group.25. The method of claim 21 , wherein the polymer comprises a cationic functional group.26. The method of claim 21 , wherein the polymer is non-resorbable within a body of a patient.27. The method of claim 21 , wherein the polymer is radiopaque.28. The method of claim 21 , wherein the composition comprises microspheres.29. The method of claim 21 , wherein the composition further comprises at least one of a cross-linker claim 21 , a gelatin claim 21 , or a coloring agent.30. The method of claim 21 , wherein the composition further comprises an additional radiopaque agent.31. The method of claim 21 , wherein the composition further comprises a magnetic agent.32. The method of claim 21 , further comprising:detecting a location of the polymer more than about 24 hours, more than about 48 hours, more than about a week, or more than about a month after introduction of the polymer.33. A method of embolization claim 21 , comprising: a polymer comprising a polymerized monomer comprising a polymerizable group; a spacer; an anionic functional group; and an iodine;', 'wherein the polymer is radiopaque., 'injecting an embolic composition into a blood vessel of a patient, the composition comprising35. The method of claim 33 , further comprising:detecting a location of the polymer more than about 24 hours, more than about 48 hours, more than about a week, or more than about a month after introduction of the polymer.36. The method of claim 33 , wherein the polymer is non-resorbable within a body of the patient.37. The method of claim 33 , wherein the composition comprises microspheres.38. A method of embolization claim 33 , ...

IODINATED DERIVATIVES, PREPARATION AND USE THEREOF AS CONTRAST AGENTS IN X-RAY RADIOLOGY

Polyiodinated derivatives of formula (I), wherein A is residue of an aromatic or aliphatic melecule; Za, Zb, Zc and Zd are Tz-Qz-Vz where Tz and Vz may be O, COND or NDCO, D may be H, alkyl or C1-6 hydroxyalkyl and Qz may be alkylene or hydroxyalkylene having 1 to 6 carbon atoms, or else Vz has the previous meaning or Qz and/or Tz are absent; Xa, Xb, Xc and Xd, which are the same or different, are (II), wherein Ar and Ar' are tri- or tetraiodinated phenyl groups with one or two optionally hydroxylated alkyl-substituted amide groups, and T, Q and V have one of the meanings of Tz, Qz or Vz, or X is (II'), wherein Ap and A'p have formula (II) above and T, Q and V have one of the meanings of Tz, Qz or Vz. Said materials are useful as contrast agents in X-ray radiology.

CONTRAST AGENT FOR 3D EX VIVO IMAGING OF VASCULAR AND TUBULAR STRUCTURES IN THE KIDNEY

САМОРАССАСЫВАЮЩИЕСЯ РЕНТГЕНОКОНТРАСТНЫЕ ПО СВОЕЙ ПРИРОДЕ ПОЛИМЕРЫ ДЛЯ МНОГОЦЕЛЕВОГО ИСПОЛЬЗОВАНИЯ

Изобретение относится к рентгеноконтрастному по своей природе биосовместимому, саморассасывающемуся полимеру, пригодному при изготовлении медицинских устройств (например, стентов), предназначенных для размещения в участке, выбранном из сосудистой, костно-мышечной/ортопедической, нервной, респираторной, репродуктивной, мочевой, пищеварительной, эндокринной, кроветворной или покрывной системы. Полимер содержит одно или более повторяющихся звеньев формулы (I) ! ! Настоящее изобретение также относится к системе для лечения участка внутри сосуда, содержащей стент и катетер, имеющий средства развертывания, а также к способу повторного лечения полости тела. Стенты, выполненные из заявленного полимера или покрытые таким полимером, являются гемосовместимыми для предотвращения острых тромбозов, препятствуют соединению и росту клеток гладкомышечной ткани сосудов, отвечающих за распространение рестеноза, а также сохраняют механическую прочность в течение длительного периода времени и могут использоваться ...

САМОРАССАСЫВАЮЩИЕСЯ РЕНТГЕНОКОНТРАСТНЫЕ ПО СВОЕЙ ПРИРОДЕ ПОЛИМЕРЫ ДЛЯ МНОГОЦЕЛЕВОГО ИСПОЛЬЗОВАНИЯ

... 1. Рентгеноконтрастный по своей природе биосовместимый, саморассасывающийся полимер, где указанный полимер содержит одно или более повторяющихся звеньев формулы (I): где X1 и X2 каждый независимо выбран из группы, состоящей из Br и I; у1 и у2 каждый независимо представляет собой ноль или целое число в диапазоне от 1 до 4, при условии, что сумма у1 и у2, равна, по крайней мере, 1; R1 представляет собой ; R13 и R14 каждый независимо выбирают из группы, состоящей из -СН=СН-, -(СН2)C-, -(CHJ1)-, -CHJ2-CHJ3-, -CH=CH-(CHJ1)-, и -(CH2)c-(CHJ1)-; с представляет собой ноль или целое число в диапазоне от 1 до 8; J1, J2 и J3 каждый независимо выбирают из группы, состоящей из Н, Br, I, - NH-Q2 и -C(=Z8)-OQ3; Q1, Q2 и Q3 каждый независимо представляет собой Н или некристаллизующуюся группу, содержащую от 1 до приблизительно 30 атомов углерода; Z7 и Z8 каждый независимо представляет собой О или S; А1 выбирают из группы, состоящей из , and ; R5 выбирают из группы, состоящей из Н, C1-С30алкила, и C1-С30гетероалкила ...

ИОДСОДЕРЖАЩИЕ ДЕНДРИМЕРНЫЕ ПОЛИМЕРЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ДИАГНОСТИЧЕСКОЕ СРЕДСТВО ДЛЯ РЕНТГЕНОДИАГНОСТИКИ

FIELD: medicine. SUBSTANCE: described are new dendrimeric polymers of general formula I: A-(X) b (1), wherein A, X and b are as defined in claim 1. They are useful as X- ray diagnostic agents. Also described are method of preparing thereof and diagnostic agent for X-ray diagnostics. X-ray contrast compounds are intended for identification and localization of cardiovascular diseases, they are easily tolerated, highly efficient and have longer half life. EFFECT: improved properties of the title polymers. 13 cl, 19 ex, 2 dwg Сб ДУС ПЧ Го (19) РОССИЙСКОЕ АГЕНТСТВО ПО ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ ВИ” 2 147 592‘ (51) МПК? 13) 49/04 СЛ С 08 С 73/02, 69/00, Аб1 К 12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ РОССИЙСКОЙ ФЕДЕРАЦИИ (21), (22) Заявка: 96115179/04, 21.12.1994 (24) Дата начала действия патента: 21.12.1994 (30) Приоритет: 22.12.1993 ОЕ Р 4344 464.4 (46) Дата публикации: 20.04.2000 (56) Ссылки: МО 93108424 А, 1993. ЗЦ 1816769 А, 1993. МО 90/12050 А, 1990. ЕР 430863 А, 1991. М/О 87/0075Г А, 1987. ММО 90/00408 А, 1990. (85) Дата перевода заявки РСТ на национальную фазу: 22.07.1996 (86) Заявка РСТ: ЕР 94/04245 (21.12.1994) (87) Публикация РСТ: М/О 95/17448 (29.06.1995) (98) Адрес для переписки: 129010, Москва, ул.Б.Спасская, д.25, стр.3, "Городисский и партнеры", Лебедевой Н.Г. (71) Заявитель: Шеринг АГ (ОЕ) (72) Изобретатель: Вернер Краузе (ОЕ), (73) Франц-Карл Майер (0Е), Михель Бауер (ОЕ), Габриель Шуманн-Жиампьери (ОЕ) , Вольф-Рюдигер Пресс (0Е) Патентообладатель: Шеринг АГ (ОЕ) (54) ИОДСОДЕРЖАЩИЕ ДЕНДРИМЕРНЫЕ ПОЛИМЕРЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ДИАГНОСТИЧЕСКОЕ СРЕДСТВО ДЛЯ РЕНТГЕНОДИАГНОСТИКИ (57) Реферат: Описываются новые иодсодержащие дендримерные полимеры общей формулы (1): А-(Х)б, где значения А, Х, 6 указаны в п. 1 формулы изобретения, они являются ценными рентгенодиагностическими средствами. Описывается также способ их получения и диагностическое средство для рентгенодиагностики. Технический результат - получение рентгеноконтрастных соединений для распознавания и ...

ПОЛИМЕРЫ С КРИСТАЛЛИЗУЮЩИМИСЯ БОКОВЫМИ ЦЕПЯМИ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ

... 1. Полимер, содержащий основную цепь, множество кристаллизующихся боковых цепей, и множество тяжелых атомов, присоединенных к этому полимеру, тяжелые атомы присутствуют в таком количестве, которое является эффективным для обнаружения рентгеноконтрастности полимера. 2. Полимер по п.1, имеющий температуру плавления в диапазоне приблизительно от 30°С до 80°С. 3. Полимер по п.1, который является биосовместимым. 4. Полимер по п.1, который является саморассасывающимся. 5. Полимер по п.1, у которого множество тяжелых атомов содержит атом, имеющий атомное число, по крайней мере, 17. 6. Полимер по п.5, у которого множество тяжелых атомов содержит атом, имеющий атомное число, по крайней мере, 35. 7. Полимер по п.1, у которого множество тяжелых атомов содержит атом, выбранный из группы, состоящей из брома, иода, висмута, золота, платины, тантала, вольфрама и бария. 8. Полимер по п.1, у которого множество тяжелых атомов ковалентно присоединяются к полимеру. 9. Полимер по п.1, у которого множество тяжелых ...

STRIKT ALTERNIERENDE POLY(ALKYLENOXID)COPOLYMERE

ROENTGENKONTRASTMITTEL

IODO DERIVATIVES YOUR PRODUCTION AND USE AS CONTRAST MEANS FOR ROENTGEN RADIOLOGY

IODIERTE POLYMERS, PROCEDURE FOR YOUR PRODUCTION AND YOUR USE AS CONTRAST MEANS.

JODHALTIGE POLYMERS WITH SKELETONS OF DEXTRAN, PROCEDURES FOR YOUR PRODUCTION AND YOUR USES AS CONTRAST MEANS.

CASCADE POLYMERS WITH IODINE AROMATICS

PSEUDOPOLYROTAXANE

POLYAMINOSÄUREN METALLKOMPLEXE ONE AND YOUR APPLICATION IN DIAGNOSTIC IMAGING

IMPLANTIERBARE PARTICLES FOR THE INCREASE OF THE FABRIC VOLUME AND FOR THE TREATMENT OF GASTROÖSOPHAGALREFLUX, INCONTINENCE AND SKIN FOLDS

ROENTGEN DENSITY POLYMERI BIOMATERIALE

Use of polycarbonates containing iodine phenyl carbonate for producing special shaped parts

Side-chain crystallizable polymers for medical applications

Radio-opaque polymer biomaterials

RADIOPAQUE CYANOACRYLATES

RADIOPAQUE CYANOACRYLATES Abstract Radiopaque cyanoacrylate compositions for use in sur-gical and other medical applications. The compositions comprise a mixture of cyanoacrylate monomer and a radio-paque additive stable to the monomer. The additives may be organic iodo compounds or certain cyanoacrylate stable inorganic compounds. Organic iodoacids can serve the addi-tional function of an anionic inhibitor for the monomer.

IODINATED POLYMERS; PROCESS FOR PREPARING THE SAME AND THEIR USE AS CONTRAST AGENTS

L'invention a pour objet des polymères iodés comprenant un squelette constitué par un dextrane sur lequel sont greffés des groupes de formule I Ces composés sont utilisables comme produits de contraste en radiographie, et notamment comme produits de contraste injectables.

ORGANIC RADIOGRAPHIC CONTRASTING AGENTS FOR MEDICAL DEVICES

The present invention discloses an organic radiographic contrasting agent containing an aliphatic or alicyclic backbone and multiple halogen-substituted aromatic groups. Each of the halogen-substituted aromatic groups in the radiographic contrasting agent is substituted with at least three halogen atoms and is covalently attached to the aliphatic or alicyclic backbone. The present invention also discloses a radio-opaque polymeric material comprising the radiographic contrasting agent and at least one polymer. The radiographic contrasting agent is physically admixed with the at least one polymer or physically embedded or dispersed in the at least one polymer. The radio-opaque polymeric material provides enhanced contrasting intensity in radiographic imaging. The radio-opaque polymeric material can be applied on at least a portion of one surface of a medical device. The radio-opaque polymeric material can also be used to construct a medical device, a component thereof, or a portion of a component thereof.

IMPLANTS AND BIODEGRADABLE FIDUCIAL MARKERS

INHERENTLY RADIOPAQUE POLYMERIC PRODUCTS FOR EMBOLOTHERAPY

... ²²²Preferred embodiments relate to compositions of inherently radiopaque, ²biocompatible, bioresorbable polymeric particles and methods of using them for ²embolizing a body lumen.² ...

GEL FORMULATIONS FOR GUIDING RADIOTHERAPY

The present invention describes an X-ray contrast composition for local administration, wherein the X-ray contrast composition exhibits contrast properties and wherein at least 60% of an administrated amount of said X-ray contrast composition remains more than 24 hours within 10 cm from an injection point when the X-ray contrast composition is administrated to a human or animal body.

POLYIODO COMPOUNDS, THEIR PREPARATION AND THEIR USE IN X-RAY RADIOLOGY

Contrast agents for X-ray radiology having formula (I), wherein Ti, Vi, T'i, V'i, where i = 0, 1 or 2, are O, COND or NDCO where D is H, alkyl or hydroxyalkyl; Qi and Q'i, where i = 0, 1 or 2, are alkylene or hydroxyalkylene; Ari and Ar'i, where i = 1 or 2, are (II) or (III), wherein R, R3 and R4 are COOH, and R', R'3 and R'4 are CONR'1R'2 or N(R'1)COR'2 where R'1 and R'2 are H, C1-4 alkyl or hydroxyalkyl together comprising more than 4 OH, or R1 and R'i, where i = 0, 3 or 4, are CONR'1R'2 and N(R'1)COR'2, R'1 and R'2 together comprising at least 6 OH; or else are T-Q-V-Ar where T, Q and V may have the previous meanings and Ar has formula (II); and A is the residue of a molecule having a molar mass of less than 1200 and comprising two bonds capable of forming an amide or etheroxide group with T0 and T'0.

USE OF POLYCARBONATES CONTAINING IODINE PHENYL CARBONATE FORPRODUCING SPECIAL SHAPED PARTS

The invention relates to the use of polycarbonates containing iodine phenyl carbonate for producing special shaped parts, especially for medical applications and toys.

Gel formulations for guiding radiation therapy

Cascale polymers with iodine aromatic compounds

X-RAY CONTRAST AGENT

New iodo contrast product, process for its preparation and its use as contrast agent

Polyiodopolyaminodendrimer characterised in that it carries at least three radioopaque iodo derivatives.

RADIOPAQUE POLYMERS FOR MEDICAL DEVICES

Radiopaque polymer compositions and methods for making the compositions are provided. These radiopaque polymer compositions include polymer compositions comprising a crosslinked polymer network, the network comprising a first repeating unit derived from a monofunctional monomer and a second repeating unit derived from a multifunctional non-iodinated monomer wherein neither of the two monomers is fluorinated. Devices formed from radiopaque polymer compositions are also provided.

OCCLUSION INSTRUMENTS COMPRISING BIORESORBABLE RADIOPAQUE POLYMERIC MATERIALS, AS WELL AS RELATED PRODUCTS, METHODS AND USES

Described are occlusion instruments (1, 2, 3, 4) comprising bioresorbable and thermoplastically deformable polymers with or without shape memory characteristics, which contain radiopaque building groups in the repeat units of the polymer chains and/or are modified with bioresorbable, radiopaque nanoparticles. The polymers display sufficient strength and deformability, good bioresorbability and sufficient visibility in radiance and are particularly useful for producing metal-free occlusion instruments for closing defects of the septum in the heart, the positioning of which being monitorable using routine diagnostic methods.

CASCADE POLYMERS WITH IODINE AROMATIC COMPOUNDS

Iodine-containing dendrimer polymers have the general formula (I) A-(X)b, in which A stands for a hydrogenated core of index b, b being 1 to 8, X stands for a residue composed of (a) repetitive units S and maximum 2n image-generating residues Z, n determines the number of generations and is 1 to 10, and S and Z have different meanings. These polymers are precious X-ray diagnostic agents.

Dendritic and star-shaped contrast agents for medical devices and bioabsorbable radiopaque bulk material and method for producing same

In accordance with the present invention, a high intensity radiopaque contrast agent is disclosed. The agent may be coated on or incorporated within bulk material which may then be subsequently utilized to fabricate a radiopaque medical device. Primary effects through chemistry include higher radiopaque concentrations per unit weight of the radiopaque element or agent. Secondary effects include selective placement of the radiopaque elements which may further enhance the radiopacity of the device with reduced requirements of the radiopaque agent. Such a radiopaque contrast agent may be produced in various forms such as a dendrimer and/or incorporated as the end groups of polymeric chain. In addition one can incorporate biological and/or pharmaceutical agents in combination with the present invention.

Plastic X-ray contrast material

A material of polyurethane with covalently linked X-ray contrast material, where the polyurethane is biocompatible, stable or also biodegradable in an appropriate environment, as well as X-ray contrasting.

X-ray contrast compositions containing iodophenoxyalkanes and pharmaceutically acceptable clays

Disclosed are x-ray contrast compositions for oral or retrograde examination of the gastrointestinal tract comprising a nonionic x-ray producing agent in combination with a pharmaceutically acceptable clay in a pharmaceutically acceptable carrier; and methods for their use in diagnostic radiology of the gastrointestinal tract.

SIDE-CHAIN CRYSTALLIZABLE POLYMERS FOR MEDICAL APPLICATIONS

Inherently radiopaque side-chain crystallizable polymers (IRSCCP's) are useful in various medical applications. An example of a IRSCCP is a polymer that comprises a main chain, a plurality of crystallizable side chains, and a plurality of heavy atoms attached to the polymer, the heavy atoms being present in an amount that is effective to render the polymer radiopaque. A polymeric material that includes a IRSCCP may be fabricated into a medical device useful for at least partially occluding a body cavity. For example, such a medical device may be an embolotherapy product.

Biocompatible polymeric contrast agents and radiopaque materials for medical devices

In accordance with the present invention, a high intensity radiopaque contrast agent is disclosed. The agent may be coated on or incorporated within bulk materials, which may then be subsequently utilized to fabricate a radiopaque medical device. Primary effects through chemistry include higher radiopaque concentrations per unit weight of the radiopaque element or agent. Secondary effects include selective placement of the radiopaque elements which may further enhance the radiopacity of the device with reduced requirements of the radiopaque agent. Such a radiopaque contrast agent may be produced in various forms such as a dendrimer and/or incorporated as the end groups of polymeric chain. In addition one can incorporate biological and/or pharmaceutical agents in combination with the present invention.

USE OF POLYCARBONATES CONTAINING IODINE PHENYL CARBONATE FOR PRODUCING SPECIAL SHAPED PARTS

The invention relates to the use of polycarbonates containing iodine phenyl carbonate for producing special shaped parts, especially for medical applications and toys.

SOLID X-RAY CONTRAST MEDIUM

SOLID X-RAY CONTRASTING AGENT

PURPOSE: To provide a solid X-ray contrasting agent for digestive tracts, composed of an iodine-substituted aromatic polymer, having excellent contrasting effect, nonadhesive to the tissue in contrast to barium sulfate and free from the tendency to form a clay-like solid even after losing water. CONSTITUTION: The objective sold X-ray contrasting agent is composed of an iodine-substituted aromatic polymer having an iodine content of 1-75wt.%, preferably 30-75wt.%. The contrasting agent is mixed with water, etc., to attain a proper concentration and administered by oral administration, enema, etc. A solution having an iodine concentration of 100-700g/l is administered in an amount of 20-300ml by oral administration or a solution having an iodine concentration of 10-700g/l is applied in an amount of 200-3,000ml by enema. The polymer is a linear polymer derived from an aromatic monovinyl monomer or a crosslinked polymer derived from an aromatic monovinyl monomer and a difunctional or polyfunctional ...

ПОЛИМЕРНЫЕ ПО СУЩЕСТВУ РЕНТГЕНОКОНТРАСТНЫЕ ПРОДУКТЫ ДЛЯ ЭМБОЛОТЕРАПИИ

Изобретение относится к химико-фармацевтической промышленности, в частности к полимерным рентгеноконтрастным продуктам для эмболотерапии. Описывается эмболотерапевтический продукт, включающий полимер формулы I: ! где Х=I или Br; Y1 и Y2=0, 1, 2, 3 или 4; f=0-1; g=0-1; f+g=0-1; А выбран из: ! , , , , ! где R1 - H или алкильная группа, содержащая от 1 до 18 углеродных атомов и 0-5 гетероатомов, выбранных из О и N; R3 - алкильная, арильная или алкиларильная группа, содержащая до 18 углеродных атомов и 0-8 гетероатомов, выбранных из О и N; В - алифатическое диоловое или полиалкиленгликолевое звено; R и R2 выбраны из ! ! где R7 - -СН=СН-, -CHJ1-CHJ2- и (-СН2-)а; R8 - -СН=СН-, -CHJ1-CHJ2- и (-СН2-)n; ! а и n=0-8; J1 и J2 - Br или I; Q для R2 включает свободную карбоксильную группу и Q для каждого R выбран из группы, состоящей из водорода и сложных эфиров и амидов карбоновых кислот, где полимер включает достаточное количество атомов галогена для придания эмболотерапевтическому продукту рентгеноконтрастности ...

Roentgenkontrastmittel

Dendritic cascade polymers with hydrophilic iodineDendritic cascade polymers with hydrophilic iodine containing aromatics useful for preparation of X- containing aromatics useful for preparation of X-ray diagnostic agents for vascular diseases and foray diagnostic agents for vascular diseases and for cancer diagnosis r cancer diagnosis

Cascade polymers with hydrophilic iodine containing aromatics, i.e. polypropyleneamine-dendrimer (POPAM) as polymer with terminal amine groups and vinyl cyanide branch units, a triiodiaromatic signal group, a 1-15C carbon chain, and 1-20C alkyl groups are new. Cascade polymers of formula P-(K)m (I) are new. P = dendritic POPAM containing m terminal primary amine groups, with vinyl cyanide branch units; m = 4-128; K = a triiodoaromatic signal group, where the signal giving group K is a triiodoaromatic of formula (II) (denotes binding site of dendrimer amine group); L = straight chain, branched, optionally unsaturated 1-15C carbon chain, which can be interrupted by 1-3 S atoms, 1-5 sulfonyl groups, and can be substituted by 1-6 OH groups or 1-3 (CH2)p-COO2OH groups; p = 0-10; R1 = H or (CH2)q-COO2OH group; q = 1-10; X = OH, O-Na+, O-Meglumin+,or NR2R3; Y = OH, -O-Na+, -O-Meglumin+ or NR4R5; R2-R5 = H, straight chain or branched 1-20C alkyl, where alkyl group can be interrupted by 1-6 O atoms ...

Radiopaque polymers

Radiopaque shape memory polymers for medical devices

Radiopaque polymer compositions and methods for making the compositions are provided. These radiopaque polymer compositions include shape memory polymer compositions comprising a crosslinked polymer network, the network comprising a first repeating unit derived from a monofunctional iodinated monomer and a second repeating unit derived from a multifunctional non-iodinated monomer wherein neither of the two monomers is fluorinated. Devices formed from radiopaque polymer compositions are also provided.

Injectable microspheres for dermal augmentation and tissue bulking

The present invention relates to elastic, hydrophilic and substantially spherical microspheres useful for dermal augmentation and tissue bulking. The invention provides injectable compositions comprising the microspheres and a biocompatible carrier for use in dermal augmentation. The present invention further provides methods of dermal augmentation and tissue bulking, particularly for the treatment of skin contour deficiencies, Gastro-esophageal reflux disease, urinary incontinence, and urinary reflux disease, using the injectable compositions.

Implants and biodegradable fiducial markers

Implantable materials may be used in an iatrogenic site. Applications include radioopaque materials for fiducial marking. Applications include a method of treating a patient with a pharmaceutically acceptable implant system comprising implanting a collection of pharmaceutically acceptable, covalently-crosslinked hydrogel particles, wherein the collection comprises a plurality of sets of the particles, with the sets having different rates of biodegradation.

Compounds And Methods For Selective Imaging And/Or Ablation

The invention relates generally to compounds and methods for imaging and/or selective ablation of nitroreductase-expressing cells and/or biological agents. More particularly, although not exclusively, the invention provides compounds that are selectively metabolised by bacterial nitroreductases and are substantially insensitive to metabolism under oxic or hypoxic conditions by human nitroreductase enzymes. 2. (canceled)3. (canceled)4. The method as claimed in claim 1 , wherein the method comprises a method of immunohistochemical imaging and wherein Y is selected from IIIb claim 1 , IIIc or IIIh and R is selected from CHF or CHF.5. (canceled)921-. (canceled)22. A method of treatment or diagnosis of a disease using the compound of claim 6 , wherein the disease is selected from the group consisting of cancer claim 6 , Parkinson's disease claim 6 , Alzheimer's disease claim 6 , stroke claim 6 , heart disease claim 6 , rheumatological diseases and a disease treated by stem-cell transplantation.2331-. (canceled) The invention relates generally to compounds that have utility in imaging and/or selective ablation of nitroreductase-expressing cells or biological agents. More particularly, although not exclusively, said compounds have use in non-invasive imaging techniques, monitoring of therapeutic cell populations and gene-directed enzyme prodrug therapy.Selective targeting of cancer tissues can be achieved by tumour-tropic organisms, including certain replication competent viral vectors and bacteria. Such organisms are generally antineoplastic in their own right, and a number are in clinical trials (or clinical use) as novel therapeutic agents. Ideally such agents would be introduced via systemic administration, and would “seek out” cancerous tissues. However, applications to date have been limited owing to an inability to non-invasively image the location of viruses or bacteria in the body post-administration. The self-amplifying nature and uncertain tropism for human ...

Polymeric treatment compositions

Polymeric compositions are described comprising a biocompatible polymer including a biodegradable linkage to a visualization agent and a non-physiological pH solution; wherein the biocompatible polymer is soluble in the non-physiological pH solution and insoluble at a physiological pH. Methods of forming the solutions and polymers are disclosed as well as methods of therapeutic use.

POLYMERIC TREATMENT COMPOSITIONS

Polymeric compositions are described comprising a biocompatible polymer including a biodegradable linkage to a visualization agent and a non-physiological solution; wherein the biocompatible polymer is soluble in the non-physiological solution and insoluble in a physiological solution. Methods of forming the solutions and polymers are disclosed as well as methods of therapeutic use. 1. A polymeric composition comprising: 'a first monomer including a biodegradable linkage to a visualization agent, and a second monomer including at least one hydroxyl group; and', 'a substantially stable biocompatible polymer comprising a reaction product ofwherein the substantially stable biocompatible polymer is dissolved in a solution.2. The polymeric composition of claim 1 , wherein the visualization agent includes at least one aromatic ring.3. The polymeric composition of claim 2 , wherein the at least one aromatic ring at least one iodine atom.4. The polymeric composition of claim 1 , wherein the solution is a non-physiological solution.5. The polymeric composition of claim 4 , wherein the non-physiological solution is a water miscible solvent.6. The polymeric composition of claim 5 , wherein the concentration of the substantially stable biocompatible polymer in the water miscible solvent is about 1% to about 50%.7. The polymeric composition of claim 1 , wherein the second monomer is hydroxyethyl methacrylate.8. The polymeric composition of claim 1 , wherein the biodegradable linkage is Seq. ID 1 claim 1 , Seq. ID 2 claim 1 , Seq. ID 3 claim 1 , Seq. ID 4 claim 1 , Seq. ID 5 claim 1 , Seq. ID 6 claim 1 , Seq. ID 7 claim 1 , Seq. ID 8 claim 1 , Seq. ID 9 claim 1 , Seq. ID 10 claim 1 , Seq. ID 11 claim 1 , or Seq. ID 12.9. The polymeric composition of claim 1 , wherein the biodegradable linkage is an ester or a polyester.10. The polymeric composition of claim 1 , wherein the substantially stable biocompatible polymer is a reaction product of 2-oxo-2-(1-oxo-1-(1-oxo-1-(2 claim 1 ,4 ...

IMAGEABLE EMBOLIC MICROSPHERE

This invention concerns imageable, radiopaque embolic beads, which are particularly useful for monitoring embolization procedures. The beads comprise iodine containing compounds which are covalently incorporated into the polymer network of a preformed hydrogel bead. The beads are prepared by activating pre-formed hydrogel beads towards nucleophilic attack and then covalently attaching iodinated compounds into the polymer network. The radiopaque beads may be loaded with chemotherapeutic agents and used in methods of embolizing hyperplastic tissue or solid tumors. 1. An activated hydrogel bead which has been activated towards nucleophilic substitution reaction with carbonyl diimidazole or carbodiimide.2. An activated hydrogel bead according to in which the hydrogel comprises a polyhydroxy polymer such as polyvinyl alcohol (PVA) or copolymers of vinyl alcohol.3. An activated hydrogel bead according to or in which the hydrogel has a polymer backbone with a 1 claim 1 ,2-diol and/or a 1 claim 1 ,3-diol structure to enable crosslinking with an acrylic monomer.4. An activated hydrogel bead according to in which the acrylic monomer is 2-acrylamido-2-methylpropane sulfonic acid (AMPS).5. An activated hydrogel bead according to any of to in which hydroxyl moieties on and/or within the preformed hydrogel bead are activated by reaction with carbonyldiimidazole.6. A method of activating a hydrogel bead towards nucleophilic substitution comprising the steps of: (i) suspending hydrogel beads in organic solvent until they have swollen; (ii) adding carbonyldiimidazole or a carbodiimide to the suspension of swollen beads in solvent claim 3 , in the presence of a catalytic amount of a base and under anhydrous conditions to achieve activation.7. A method according to which further comprises step (iii) in which the activated beads are filtered and washed with organic solvent to provide purified activated beads.8. A radiopaque hydrogel bead comprising the activated hydrogel bead of any of ...

CYCLIC CARBONATE MONOMER CONTAINING DOUBLE IODINE, BIODEGRADABLE POLYMER PREPARED THEREBY AND USE

The disclosure relates to a cyclic carbonate monomer containing double iodine, a biodegradable polymer prepared thereby and use. The polymer can be obtained by ring-opening polymerization of the cyclic carbonate monomer containing double iodine, without affecting the ring-opening polymerization and without a protection and deprotection process. The polymer which is obtained by ring-opening polymerization of the cyclic carbonate monomer of the present disclosure can be assembled into a nano-vesicle and a micelle as a drug carrier, a biological tissue scaffold or a CT contrast media. 2. A method for preparing the cyclic carbonate monomer containing double iodine of claim 1 , wherein the method comprises the following steps: in a low-boiling point solvent claim 1 , reacting dibromoneopentyl glycol with metal iodide to obtain Compound A; then in nitrogen atmosphere and cyclic ether-based solvent claim 1 , reacting Compound A with ethyl chloroformate and triethylamine to obtain the cyclic carbonate monomer containing double iodine.4. The biodegradable polymer containing a functional group of double iodine in the side chain according to claim 3 , wherein the amount of iodine in the molecular chain of aforesaid biodegradable polymer containing a functional group of double iodine in the side chain is 5%-65%.5. The biodegradable polymer containing a functional group of double iodine in the side chain according to claim 3 , wherein cyclic ester monomer is glycolide claim 3 , caprolactone or lactide; said other carbonate monomer is cyclic carbonate containing double-sulfur claim 3 , 2 claim 3 ,4 claim 3 ,6-trimethoxybenzylidene-pentaerythritol carbonate or trimethylene cyclic carbonate.6. The biodegradable polymer containing a functional group of double iodine in the side chain according to claim 3 , wherein the cyclic carbonate monomer containing double iodine is polymerized in the form of polyethylene glycol claim 3 , ethylene glycol claim 3 , isopropanol or propynol as the ...

Embolic compositions

Described herein are compositions comprising, a polymer; a non-physiological solution; and a visualization agent; wherein the polymer is soluble in the non-physiological solution and insoluble at physiological conditions. Methods of preparing the compositions are disclosed as well as methods of using these compositions to treat vascular conditions.

ACTIVITY BASED PROBE AND USES THEREOF FOR IMAGING

Provided is a compound including at least one carrier moiety associated with a plurality of CT imaging moieties, and with at least one enzyme interacting moiety as well as uses thereof in diagnosis. 187-. (canceled)89. A compound comprising at least one carrier moiety associated with a plurality of CT imaging moieties , and with a cathepsin interacting moiety , whereinthe at least one carrier moiety is selected from a macromolecule, a polymer, an oligomer, a dendrimer, a nanoparticle, a liposome, a lipoplex, a polymersome, a micell and a nanotube; and whereinthe plurality of CT imaging moieties are selected from iodine-based moieties and gold-based moieties.90. The compound according to claim 88 , wherein the CT imaging moiety is an iodine-based moiety selected from iodinated moieties having molecular weights of between 1 kDa and 30 kDa.91. The compound according to claim 88 , wherein the CT imaging moiety is iodine-based moiety being an iodine-substituted aromatic moiety claim 88 , comprising one or more aryl rings claim 88 , each being optionally substituted with one or more iodine atoms; or an iodine-substituted aliphatic moiety claim 88 , being optionally a carbocyclic moiety claim 88 , substituted by one or more iodine atoms; or an iodine-substituted aryl moiety comprising between 1 and 6 iodine atoms.92. The compound according to claim 89 , wherein the gold-based moiety comprising at least one gold nanoparticle (GNP).93. The compound according to claim 92 , wherein the GNP has an average diameter of between 5 nm and 200 nm claim 92 , or between 10 nm and 100 nm claim 92 , or of 10 nm claim 92 , 30nm and 100 nm.95. The compound according to claim 88 , being of the general Formula (I):{'br': None, 'I-C-M \u2003\u2003(I)'}wherein:I is at least one CT imaging moiety;C is a carrier moiety;M is a cathepsin interacting moiety; andwherein each “-” designates at least one covalent bond, or optionally one or multiple intervening atoms or groups of atoms, forming a one- ...

RADIOPAQUE POLYMERS WITH ENHANCED RADIOPACITY

Radiopaque polymer compositions and methods for making the compositions are provided. These radiopaque polymer compositions include polymer compositions comprising a crosslinked polymer network, the network comprising a first repeating unit derived from a monofunctional monomer, a second repeating unit derived from a crosslinker monomer having more than two poly-merizable groups and a third repeating unit a derived from a crosslinker monomer having two or more polymerizable groups. Devices formed from radiopaque polymer compositions and methods for synthesizing radiopaque polymer compositions are also provided. 2. The crosslinked polymer network of claim 1 , wherein Aris an iodine containing Caryl group with 3 to 5 iodine atoms attached directly to the ring.3. The crosslinked polymer network of claim 1 , wherein Ris a C-Calkylene group.5. The crosslinked polymer network of claim 4 , wherein r is an integer selected from the range of 3 to 8.6. (canceled)8. The crosslinked polymer network of claim 7 , wherein:{'sup': '10', 'Ris O;'}{'sup': 9', '10, 'each Tand each Tare (meth)acrylate; and'}w and v are each independently integers from 1 to 6.11. The crosslinked polymer network of claim 1 , wherein said crosslinked polymer network has greater than or equal to 15 wt % of said first reagent claim 1 , said crosslinked polymer network has less than or equal to 85 wt % of said second reagent claim 1 , said crosslinked polymer network has less than or equal to 85 wt % of said third reagent claim 1 , or a combination thereof.12. (canceled)13. (canceled)14. The crosslinked polymer network of claim 1 , wherein said crosslinked polymer network comprises between 80 to 90 wt % of said first reagent claim 1 , 1 to 10 wt % of said second reagent and 5 to 15 wt % of said third reagent.15. A radiopaque polymer device for medical application claim 1 , said device or a device feature comprising a polymer composition according to claim 1 , optionally comprising a fiber claim 1 , a coil or ...

EMBOLIC MATERIAL AND METHOD FOR PRODUCING SAME

An embolic material contains at least one type of polymer and a liposoluble contrast medium. A method for producing an embolic material includes extruding a raw material that is in a molten state into a solvent, and cooling the raw material so as to solidify the raw material. The raw material contains a polymer and a liposoluble contrast medium. 1. An embolic material comprising:at least one type of polymer: anda liposoluble contrast medium.2. The embolic material according to claim 1 ,wherein the liposoluble contrast medium can contain a pharmaceutical drug.3. The embolic material according to claim 1 ,wherein the polymer is biodegradable.4. The embolic material according to claim 1 ,wherein the polymer is one or more selected from a group consisting of polycaprolactone, polylactate, a copolymer of polycaprolactone and polylactate, a mixture of polycaprolactone and polylactate, and a compound of polycaprolactone and polylactate.5. A method for producing an embolic material claim 1 , the method comprising:extruding a raw material containing at least one type of polymer and a liposoluble contrast medium into a solvent, the raw material being in a molten state; andcooling the raw material so as to solidify the raw material.6. The method for producing an embolic material according to claim 5 ,wherein the raw material extruded into the solvent forms spherical shapes.7. The method for producing an embolic material according to claim 5 ,wherein the liposoluble contrast medium can contain a pharmaceutical drug.8. The method for producing an embolic material according to claim 5 ,wherein the polymer is biodegradable.9. The method for producing an embolic material according to claim 5 ,wherein the polymer is one or more selected from a group consisting of polycaprolactone, polylactate, a copolymer of polycaprolactone and polylactate, a mixture of polycaprolactone and polylactate, and a compound of polycaprolactone and polylactate. This international application claims the ...

RADIOPAQUE POLYMERS FOR MEDICAL DEVICES

Radiopaque polymer compositions and methods for making the compositions are provided. These radiopaque polymer compositions include polymer compositions comprising a crosslinked polymer network, the network comprising a first repeating unit derived from a monofunctional monomer and a second repeating unit derived from a multifunctional non-iodinated monomer wherein neither of the two monomers is fluorinated. Devices formed from radiopaque polymer compositions are also provided. 4. The polymer composition of claim 1 , wherein the amount of the first repeating unit in the polymer composition is from 15 to 35 wt %.5. The polymer composition of claim 1 , wherein the amount of the second repeating unit in the polymer composition is from 65 to 85 wt %.10. The polymer composition of claim 7 , wherein the amount of the first monomer is from 15 to 35 wt % of the monomer mixture.15. The method of claim 12 , wherein the amount of the first monomer is from 15 to 35 wt % of the monomer mixture.1728. The method of claim 16 , wherein the amount of the first monomer is from 15 to 35 wt %. and the combined amount of the second monomer and the monomer of claim is from 85 to 65 wt % of the monomer mixture. This application is a continuation of U.S. patent application Ser. No. 15/706,560, filed Sep. 15, 2017, which is a continuation of U.S. patent application Ser. No. 14/766,626, with a § 371(c) date of Aug. 7, 2015, now U.S. Pat. No. 9,789,231, which is a U.S. National Stage Application under 35 U.S.C. § 371 of International Application No. PCT/US2014/015250, filed Feb. 7, 2014, which claims the benefit of U.S. Provisional Application No. 61/762,416, filed Feb. 8, 2013, each of which are hereby incorporated by reference in their entirety.Shape memory materials are defined by their capacity to recover a predetermined shape after significant mechanical deformation (K. Otsuka and C. M. Wayman, “Shape Memory Materials” New York: Cambridge University Press, 1998). The shape memory effect ...

IODINE-BASED PARTICLES

Described herein are iodine-based particles which can be used as contrast agents for x-ray radiology. Also described herein are methods, software modules and hardware modules for imaging iodine-based particles. 1. An iodine nanoparticle which is a reaction product of functionalized triiodobenzene , linking monomers , and biocompatible polymers;wherein said functionalized triiodobenzene, said linking monomers, and said biocompatible polymers are covalently cross-linked resulting in the structure of said nanoparticle being non-dendritic, non-uniform, and non-linear;wherein said nanoparticle has a polydispersity index of about 0.5 or less;wherein said nanoparticle has sufficient iodine density to be imaged by an imaging device following administration to a subject; andwherein said nanoparticle provides for an extended blood half-life.2. The nanoparticle according to wherein said functionalized triiodobenzene is functionalized 1 claim 1 ,3 claim 1 ,5-triiodobenzene or functionalized 2 claim 1 ,4 claim 1 ,6-triiodobenzene.4. The iodine nanoparticle according to wherein said functionalized triiodobenzene is 2 claim 1 ,4 claim 1 ,6-triiodophenol claim 1 , 2-(2 claim 1 ,4 claim 1 ,6-triiodophenoxy)ethanol claim 1 , 2-(2-bromoethoxy)1 claim 1 ,3 claim 1 ,5-triiodobenzene claim 1 , (2 claim 1 ,4 claim 1 ,6-triiodophenoxy)acetamide claim 1 , 2-(2 claim 1 ,4 claim 1 ,6-triiodophenoxy)ethanesulfonic acid claim 1 , 3-hydroxy-2 claim 1 ,4 claim 1 ,6-triiodobenzoic acid claim 1 , 3-amino-2 claim 1 ,4 claim 1 ,6-triiodobenzoic acid claim 1 , methyl 2-(2 claim 1 ,4 claim 1 ,6-triiodophenoxy)butyrate claim 1 , (2-(2 claim 1 ,4 claim 1 ,6-triiodophenoxy)-ethyl)trimethylammonium methanesulfonate claim 1 , 5-amino-2 claim 1 ,4 claim 1 ,6-triiodoisophthalic acid claim 1 , α-ethyl-3-hydroxy-2 claim 1 ,4 claim 1 ,6-triiodohydrocinnamic acid claim 1 , iopanoic acid claim 1 , 7-(3-amino-2 claim 1 ,4 claim 1 ,6-triiodophenyl)heptanoic acid claim 1 , 7-(3-amino-2 claim 1 ,4 claim 1 ,6- ...

IMPLANTS AND BIODEGRADABLE TISSUE MARKERS

Implantable materials may be used in an iatrogenic site. Applications include radioopaque materials for fiducial marking. 115.-. (canceled)16. A method for radiation therapy comprising introducing a hydrogel spacer at a site between a first tissue location and a second tissue location to increase a distance between the first tissue location and the second tissue location , the site being chosen to decrease radiation at the first tissue when the second tissue receives a dose of therapeutic radiation , wherein the hydrogel spacer comprises a polysaccharide and a radioopaque agent.17. The method of claim 16 , wherein the polysaccharide is hyaluronic acid.18. The method of claim 16 , wherein the radioopaque agent is a covalently attached radiopaque iodine agent.19. The method of claim 16 , wherein the first tissue location is associated with the rectum and the second tissue location is associated with the prostate gland.20. The method of claim 16 , wherein the spacer provides a fiducial marker for administration of the therapeutic radiation.21. The method of claim 20 , further comprising visualizing the interface of the fiducial marker and the second tissue.22. The method of claim 21 , wherein the visualizing comprises computerized tomography or X-ray.23. The method of claim 16 , further comprising making a radiation plan based on a visualization of the hydrogel spacer claim 16 , with the hydrogel spacer being in contact with the second tissue.24. The method of claim 23 , with the plan having a reduced uncertainty in target definition relative to a radiation plan made without the hydrogel spacer.25. The method of claim 16 , wherein the hydrogel spacer has a Hounsfield number of more than about 50.26. The method of claim 16 , wherein the hydrogel spacer claim 16 , as placed in the tissue claim 16 , has a volume between 1 and 40 ml.27. The method of claim 16 , further comprising visualizing margins of the hydrogel spacer with a machine selected from computerized ...

LYSINE OLIGOMER DERIVATIVE AND CARTILAGE TISSUE MARKER MADE THEREOF

There is provided a lysine oligomer derivative, wherein an ε-amino group and a carboxyl group of lysines are linked via a peptide bond, and a group capable of generating or absorbing electromagnetic wave is bonded to a C-terminal carboxyl group, an N-terminal amino group and/or an α-amino group. This lysine oligomer derivative has the characteristic of specifically accumulating in the cartilage matrix and can generate or absorb an electromagnetic wave, and is, therefore, useful as a cartilage tissue marker. 1. A lysine oligomer derivative , wherein an ε-amino group and a carboxyl group of lysines are linked via a peptide bond , and a group capable of generating or absorbing electromagnetic wave is bonded to a C-terminal carboxyl group , an N-terminal amino group and/or an α-amino group.2. The lysine oligomer derivative according to claim 1 , wherein 3 to 12 lysines are linked.3. The lysine oligomer derivative according to claim 1 , wherein the group capable of generating or absorbing electromagnetic wave is a fluorescent group or a group for radiographic visualization.4. The lysine oligomer derivative according to claim 3 , wherein the group capable of generating or absorbing electromagnetic wave is an iodine-containing group for radiographic visualization.5. A cartilage tissue marker made of the lysine oligomer derivative according to .6. The cartilage tissue marker according to claim 5 , wherein 3 to 12 lysines are linked.7. The cartilage tissue marker according to claim 5 , wherein the group capable of generating or absorbing electromagnetic wave is a fluorescent group or a group for radiographic visualization.8. The cartilage tissue marker according to claim 7 , wherein the group capable of generating or absorbing electromagnetic wave is an iodine-containing group for radiographic visualization.9. (canceled)10. A carrier for delivering a drug to a targeted cartilage which comprises a lysine oligomer derivative claim 7 , wherein an ε-amino group and a carboxyl ...

INHERENTLY RADIOPAQUE POLYMERIC PRODUCTS FOR EMBOLOTHERAPY

Preferred embodiments relate to compositions of inherently radiopaque, biocompatible, bioresorbable polymeric particles and methods of using them for embolizing a body lumen. 2. The embolotherapy product of claim 1 , wherein said polymer further comprises a homopolymer claim 1 , a heteropolymer claim 1 , or a blend thereof.3. (canceled)512-. (canceled)13. The embolotherapy product of claim 1 , wherein{'sub': 1', '4, 'said polymer is copolymerized with a poly(C-Calkylene glycol).'}14. The embolotherapy product of claim 13 , wherein said poly(C-Calkylene glycol) is present in a weight fraction of less than about 75 wt %.15. The embolotherapy product of claim 14 , wherein said poly(alkylene glycol) is poly(ethylene glycol).16. The embolotherapy product of claim 13 , wherein between about 0.01 and about 0.99 percent of said polymer units comprise a pendant —COOH group.1728-. (canceled)30. The embolotherapy product of claim 29 , wherein P is a poly(ethylene glycol) that is present in a weight fraction of about 50% or less.31. (canceled)32. The embolotherapy product of claim 29 , wherein both R and Rcomprise a pendant COORgroup;{'sub': '1', 'wherein for R, the subgroup Ris independently an alkyl group ranging from 1 to about 18 carbon atoms containing from 0 to 5 heteroatoms selected from O and N; and'}{'sub': 2', '1, 'wherein for R, the subgroup Ris a hydrogen atom.'}3639-. (canceled)40. The embolotherapy product of claim 29 , wherein Rof said polymer is a moiety selected from the group consisting of —CH—C(═O)— claim 29 , —CH—CH—C(═O)— claim 29 , —CH═CH— and (—CH—)z claim 29 , wherein z is an integer from 1 to 8 claim 29 , inclusive.41. The embolotherapy product of claim 29 , wherein all X groups are ortho-directed.42. The embolotherapy product of claim 29 , wherein Y1 and Y2 are independently 2 or less claim 29 , and Y1+Y2=1 claim 29 , 2 claim 29 , 3 or 4.43. The embolotherapy product of claim 42 , wherein all X groups are iodine.44. The embolotherapy product of claim ...

Gel formulations for guiding radiotherapy

The present invention describes an X-ray contrast composition for local administration, wherein the X-ray contrast composition exhibits contrast properties and wherein at least 60% of an administrated amount of said X-ray contrast composition remains more than 24 hours within 10 cm from an injection point when the X-ray contrast composition is administrated to a human or animal body.

IMAGEABLE POLYMERS

The present invention relates to hydrogels comprising 1,2-diol or 1,3-diol groups acetalised with a radiopaque species of one or more covalently bound radiopaque halogens which are imageable during embolization therapy. The invention further relates to methods of making radiopaque polymers and radiopaque hydrogel microspheres to provide an imageable drug delivery system. 1. A hydrogel comprising 1 ,2-diol or 1 ,3-diol groups acetalised with a radiopaque species the radiopaque species comprising one or more covalently bound radiopaque halogens.2. A hydrogel according to comprising 1 claim 1 ,2-diol or 1 claim 1 ,3-diol groups acetalised with a radiopaque species such that that the polymer comprises an iodinated aromatic group covalently bound to the polymer through cyclic acetal linkage.3. A hydrogel according to claim 1 , wherein the hydrogel is a cross-linked polymer network.4. A hydrogel according to wherein the hydrogel comprises polyvinyl alcohol (PVA) in which the PVA comprises pendent actetate groups formed from the acetalisation of PVA with N-acryloyl-aminoacetaldehyde dimethylacetal and which is cross-linked with 2-acrylamido-2-methylpropanesulfonic acid (PVA-AMPS).5. A hydrogel according to wherein the radiopaque species is acetalised in the hydrogel in the form of a cyclic acetal.6. A hydrogel according to wherein the radiopaque species is selected from iodine and bromine.7. A hydrogel according to wherein the radiopaque species comprises an iodinated or brominated phenyl group.8. A hydrogel according to wherein the hydrogel comprises greater than 10% iodine by dry weight.9. A hydrogel according to wherein the hydrogel is in the form of microparticles or microspheres.10. A hydrogel according to wherein the hydrogel is in the form of microspheres with a mean diameter size range of from 10 to 2000 μm.11. A hydrogel according to in the form of microspheres or microparticles having a mean radiopacity of 500 HU or greater.12. A hydrogel according to wherein the ...

IMAGEABLE POLYMERS

This invention relates to imageable polymers, particularly those comprising poly vinylalcohol and to methods for making them as well as to embolic microspheres comprising the polymers. The microspheres are imageable during embolization procedures and can be loaded with drugs or other therapeutic agents to provide an imageable drug delivery system 137.-. (canceled)38. Hydrogel polymer microspheres wherein the hydrogel polymer comprises: a polyvinyl alcohol (PVA) backbone comprising at least two pendant chains having cross-linkable ethylenically unsaturated functional groups which are cross linked by a vinylic co-monomer;the PVA backbone further comprising 1,3-diol groups acetalised with a radiopaque species which is coupled to the hydrogel polymer through a cyclic acetal group, the radiopaque species comprising one or more covalently bound iodines.39. Hydrogel polymer microspheres according to wherein the pendant chains comprising cross-linkable ethylenically unsaturated functional groups are attached to the 1 claim 38 ,3-diol groups of the PVA backbone via cyclic acetal linkages.40. Hydrogel polymer microspheres according to wherein the vinylic co-monomer is 2-acrylamido-2-methylpropanesulfonic acid.41. Hydrogel polymer microspheres according to wherein the ethylenically unsaturated functional groups are acrylate groups.42. Hydrogel polymer microspheres according to wherein the radiopaque species comprises an iodinated phenyl group.44. Hydrogel polymer microspheres according to wherein claim 43 , Z is (i) a methylene or ethylene group or is (ii) a group —(CH)—O—(CH)— wherein q is 0 claim 43 , 1 or 2 and p is 1 or 2 or is (iii) absent.45. Hydrogel polymer microspheres according to wherein claim 43 , Z is —CHO— claim 43 , —(CH)O— claim 43 , —CHOCH— claim 43 , —(CH)O(CH)— or is absent.46. Hydrogel polymer microspheres according to wherein Hal is 3 or 4 iodines.47. Hydrogel polymer microspheres according to wherein Hal is 2 claim 43 ,3 claim 43 ,5 triiodo claim 43 , 2 ...

RADIOPAQUE POLYMERS FOR MEDICAL DEVICES

Radiopaque polymer compositions and methods for making the compositions are provided. These radiopaque polymer compositions include polymer compositions comprising a crosslinked polymer network, the network comprising a first repeating unit derived from a monofunctional monomer and a second repeating unit derived from a multifunctional non-iodinated monomer wherein neither of the two monomers is fluorinated. Devices formed from radiopaque polymer compositions are also provided. 2) (canceled)3) (canceled)4) The polymer composition of claim 1 , wherein Aris Caryl substituted with three I atoms claim 1 , and wherein Rand Rare independently C-Calkylene.5) (canceled)6) (canceled)7) (canceled)8) (canceled)9) The polymer composition of claim 1 , wherein the amount of the first repeating unit in the polymer composition is from 40-80 wt %.10) The polymer composition of claim 9 , wherein the amount of the second repeating unit in the polymer composition is at most 40 wt % of the composition.11) (canceled)12) (canceled)13) (canceled)14) (canceled)15) (canceled)16) (canceled)17) (canceled)19) (canceled)20) (canceled)21) The polymer composition of claim 18 , wherein Aris Caryl substituted with three I atoms claim 18 , and wherein Rand Rare independently C-Calkylene.22) (canceled)23) (canceled)24) (canceled)25) (canceled)26) The polymer composition of claim 18 , wherein the amount of the first monomer is from 40-80 wt % of the monomer mixture.27) (canceled)28) (canceled)29) (canceled)30) (canceled)31) (canceled)32) (canceled)34) (canceled)35) (canceled)36) (canceled)37) (canceled)38) (canceled)39) (canceled)40) (canceled)41) The method of claim 33 , wherein Aris Caryl substituted with three I atoms claim 33 , and wherein Rand Rare independently C-Calkylene.42) (canceled)43) (canceled)44) (canceled)45) (canceled)46) The method of claim 33 , wherein the amount of the first monomer is from 40-80 wt % of the monomer mixture.47) (canceled)48) (canceled)49) (canceled)50) The method of ...

RADIOPAQUE PARTICLE COMPOSITIONS AND USES THEREOF

Compositions and emulsions are described, which are useful in treating disease. 1. A composition comprising:a pharmaceutical ingredient;a component of poppy seed oil selected from palmitic acid, stearic acid, oleic acid, linoleic acid, myristic acid, heptadecanoic acid, arachidic acid, γ-tocopherol, a glyceride, or a combination thereof;a biodegradable radiopaque polymeric particle comprising a visualization agent and: PLGA monomer; PLLA monomer; PLLA monomer and PLA monomer; PEG diacrylamide monomer, glycerol monomethacrylate monomer, 2-amino ethyl methacrylate monomer, and N,N-methylenebisacrylamide monomer; PEG diacrylamide monomer, amino propyl methacrylamide monomer, and 3-sulfopropyl acrylate potassium salt monomer; or PCL monomer and gelatin.2. The composition of claim 1 , wherein the pharmaceutical ingredient is axitinib claim 1 , bosutinib claim 1 , cabozantinib claim 1 , canertinib claim 1 , dasatinib claim 1 , dovitinib claim 1 , doxorubicin claim 1 , epirubicin claim 1 , erlotinib claim 1 , gefitinib claim 1 , gemcitabine claim 1 , idarubicin claim 1 , imatinib claim 1 , lapatinib claim 1 , lestaurtinib claim 1 , levatinib claim 1 , masitinib claim 1 , nilotinib claim 1 , pazopanib claim 1 , regorafenib claim 1 , sorafenib claim 1 , sunitinib claim 1 , terazosin claim 1 , vandetanib claim 1 , vatalanib claim 1 , oxaliplatin claim 1 , carboplatin claim 1 , or a pharmaceutically acceptable salt thereof.3. The composition of claim 1 , wherein the pharmaceutical ingredient is axitinib claim 1 , bosutinib claim 1 , cabozantinib malate claim 1 , canertinib diHCl claim 1 , dasatinib claim 1 , dovitinib claim 1 , doxorubicin HCl claim 1 , epirubicin HCl claim 1 , erlotinib HCl claim 1 , gefitinib claim 1 , gemcitabine claim 1 , idarubicin HCl claim 1 , imatinib methane-sulfonate claim 1 , lapatinib toluene-sulfonate claim 1 , lestaurtinib claim 1 , levatinib mesylate claim 1 , masitinib claim 1 , nilotinib claim 1 , pazopanib claim 1 , regorafenib claim 1 , ...

Liquid Embolic Compositions

The present specification discloses improved liquid embolic compositions, methods of making such liquid embolic compositions, and methods and uses for such liquid embolic compositions. 1. A liquid embolic composition comprising:from about 1% to about 20% of a miscible polymer;from about 5% to about 35% of a radiopaque contrast agent;from about 5% to about 93% of a biocompatible solvent; andfrom about 1% to about 40% of a biocompatible mixing agent that is insoluble in the biocompatible solvent;wherein the percent of each of the components is based on a total weight of the complete liquid embolic composition.2. The liquid embolic composition of claim 1 , wherein the composition comprises:from about 3% to about 10% of a miscible polymer;from about 20% to about 35% of a radiopaque contrast agent;from about 15% to about 57% of a biocompatible solvent; andfrom about 20% to about 40% of a biocompatible mixing agent that is insoluble in the biocompatible solvent;wherein the percent of each of the components is based on a total weight of the complete liquid embolic composition.3. The liquid embolic composition of claim 1 , wherein the miscible polymer is an ethylene vinyl alcohol copolymer.4. The liquid embolic composition of claim 1 , wherein the contrast agent is at least one of tantalum claim 1 , tantalum oxide claim 1 , barium sulfate claim 1 , gold claim 1 , platinum claim 1 , tungsten claim 1 , palladium claim 1 , and an iodinated contrast agent.5. The liquid embolic composition of claim 1 , wherein the biocompatible solvent is dimethyl sulfoxide or a dimethyl sulfoxide homologue.6. The liquid embolic composition of claim 1 , wherein the mixing agent has a density that is relatively greater than a density of the biocompatible solvent.7. The liquid embolic composition of claim 6 , wherein the mixing agent is at least one of polypropylene plastic claim 6 , polyethylene (“PE”) claim 6 , polyethylene terephthalate (“PET”) claim 6 , polytetrafluoroethylene (“PTFE”) claim 6 ...

INHERENTLY RADIOPAQUE POLYMERIC PRODUCTS FOR EMBOLOTHERAPY

Preferred embodiments relate to compositions of inherently radiopaque, biocompatible, bioresorbable polymeric particles and methods of using them for embolizing a body lumen. 2. The embolotherapy product of claim 1 , wherein all X groups are ortho-directed and Y is 1 or 23. The embolotherapy product of claim 1 , wherein Ris an alkyl group.5. The embolotherapy product of claim 4 , wherein Rfor at least one unit comprises a pendant —COORgroup claim 4 , wherein claim 4 , for each unit in which it is present claim 4 , the subgroup Ris independently a hydrogen or an alkyl group ranging from 1 to about 18 carbon atoms containing from 0 to 5 heteroatoms selected from O and N.9. The embolotherapy product of claim 1 , wherein said polymer is copolymerized with a poly(C-Calkylene glycol).10. The embolotherapy product of claim 9 , wherein said poly(C-Calkylene glycol) is present in a weight fraction of less than about 75 wt %.11. The embolotherapy product of claim 10 , wherein said poly(alkylene glycol) is poly(ethylene glycol).12. The embolotherapy product of claim 9 , wherein between about 0.01 and about 0.99 percent of said polymer units comprise a pendant —COOH group.13. The embolotherapy product of claim 1 , wherein Ris an aryl or alkylaryl group.14. The embolotherapy product of claim 13 , wherein the Raryl or alkylaryl group is selected so that the polymer units are diphenols.16. The embolotherapy product of claim 15 , wherein all X groups are ortho-directed.17. The embolotherapy product of claim 15 , wherein Y1 and Y2 are independently 2 or less claim 15 , and Y1+Y2=1 claim 15 , 2 claim 15 , 3 or 4.18. The embolotherapy product of claim 15 , wherein Rfor at least one unit comprises a pendant —COORgroup claim 15 , wherein claim 15 , for each unit in which said —COORgroup is present claim 15 , the subgroup Ris independently a hydrogen or an alkyl group ranging from 1 to about 18 carbon atoms containing from 0 to 5 heteroatoms selected from O and N.22. The embolotherapy ...

RADIOPAQUE POLYMERS

Radiopaque hydrogels, in particular radiopaque hydrogel microspheres comprising a polymer having 1,2-diol or 1,3-diol groups acetalised with radiopaque species. 135.-. (canceled)37. The polymer according to claim 36 , wherein Q is a phenyl group substituted by one or more iodines.38. The polymer according to claim 36 , wherein Q is a phenyl substituted by 3 or 4 iodines.39. The polymer according to claim 36 , wherein if Z is present claim 36 , Z is (i) Calkylene claim 36 , Calkoxylene or (ii) is a group —(CH)—O—(CH)— wherein q is 0 claim 36 , 1 or 2 and p is 1 or 2.40. The polymer according to claim 36 , wherein if Z is present claim 36 , Z is{'sub': 2', '2', '2', '2', '2', '2', '2', '2', '2, '—(CH)O(CH)—, —CHOCH—, —(CH)O—, or —CHO—.'}41. The polymer according to claim 36 , wherein Q is a phenyl group substituted by one or more iodines; and if Z is present claim 36 , Z is a Calkylene or a group —(CH)—O—(CH)— wherein p is 0 claim 36 , 1 or 2 and q is 1 or 2.42. The polymer according to claim 36 , further comprising greater than 10% iodine by dry weight.43. The polymer according to claim 36 , comprising greater than 30% iodine by dry weight.44. The polymer according to claim 36 , wherein the polymer is cross linked.45. The polymer according to claim 37 , wherein the polymer is cross linked.46. The polymer according to claim 38 , wherein the polymer is cross linked.47. The polymer according to claim 39 , wherein the polymer is cross linked.48. The polymer according to claim 40 , wherein the polymer is cross linked.49. The polymer according to claim 41 , wherein the polymer is cross linked.50. The polymer according to claim 42 , wherein the polymer is cross linked.51. The polymer according to claim 43 , wherein the polymer is cross linked.52. A method of making a radiopaque polyvinyl alcohol (PVA) polymer or co-polymer comprising reacting a PVA polymer or co-polymer comprising 1 claim 43 ,3-diol groups with a radiopaque species capable of forming a cyclic acetal with ...

BIODEGRADABLE COMPOSITIONS SUITABLE FOR CONTROLLED RELEASE

Simple mixing/blending of a special class of drug-depot forming tri-block copolymers polymers, with the opportunity to cost-effectively tailor drug delivery performances of such biodegradable, injectable depots in a clinical and an industrial setting. How to visualize these depots for various imaging related purposes is described. A composition comprising (a) an active ingredient, preferably a pharmaceutically active ingredient (b) a solvent and (c) a mixture of at least two types of tri-block copolymers of formula (1) 1. A composition , comprising:(a) an active ingredient,(b) a solvent and {'br': None, 'B-A-B\u2003\u2003(1)'}, '(c) a mixture of at least two types of tri-block copolymers of formula (1)'}wherein B stands for a hydrophobic block and wherein A stands for a hydrophilic block, wherein the mixture is prepared by mixing at least two types of tri-block copolymers having a degree of modification of 100% and wherein the B-A-B types of tri-block copolymers differ only on the type of end-group or wherein the mixture is prepared by mixing at least two types of tri-block copolymers, wherein one of the at least two tri-block copolymers has a degree of modification of 100% and one of the at least two tri-block copolymers has a degree of modification of 0% and wherein the B-A-B types of tri-block copolymers differ only on the degree of modification of the end-groups, and where only tri-block copolymer with a degree of modification of 100% or 0% has been added.2. The composition according to claim 1 , wherein end-group of at least one of the two types of tri-block copolymer is covalently bound to a compound containing radiopaque atoms.3. The composition according to claim 1 , wherein A stands for a linear poly-(ethylene glycol) block and wherein B stands for a hydrophobic block comprising at least one cyclic monomer selected from one or more of glycolide claim 1 , lactide claim 1 , ε-caprolactone claim 1 , p-dioxanone (1 claim 1 ,4-dioxan-2-one) claim 1 , ...

IMAGEABLE EMBOLIC MICROSPHERE

This invention concerns imageable, radiopaque embolic beads, which are particularly useful for monitoring embolization procedures. The beads comprise iodine containing compounds which are covalently incorporated into the polymer network of a preformed hydrogel bead. The beads are prepared by activating pre-formed hydrogel beads towards nucleophilic attack and then covalently attaching iodinated compounds into the polymer network. The radiopaque beads may be loaded with chemotherapeutic agents and used in methods of embolizing hyperplastic tissue or solid tumors. 136-. (canceled)37. A method of making a radiopaque hydrogel bead , comprising:preforming hydrogel beads;selecting a particular size or size range of preformed beads; andreacting functional groups on the selected preformed hydrogel beads with an aromatic iodine containing compound.38. A method according to claim 37 , wherein the aromatic iodine containing compound is an iodinated benzyl or phenyl alcohol or is an iodinated benzoic acid.39. A method according to claim claim 37 , wherein the aromatic iodine containing compound is 2 claim 37 ,3 claim 37 ,5-triiodobenzoic acid.40. A method according to claim 37 , comprising preforming the hydrogel bead from a polymer which has alcoholic hydroxyl substituents or acylated derivatives thereof.41. A method as claimed in claim 37 ,characterized in that the hydrogel beads have been reacted with carbonyl diimidazole or carbodiimide so as to be activated towards nucleopilic substitution reaction; andcharacterized in that the beads are covalently coupled with an iodinated compound which is reactive towards the imidazole or diimide functionality of the activated beads.42. A method according to claim 41 , wherein the hydrogel comprises a cross-linked polyhydroxy polymer selected from polyvinyl alcohol (PVA) or a copolymer of vinyl alcohol.43. A method according to claim 41 , wherein the hydrogel has a polymer backbone with a 1 claim 41 ,2-diol and/or a 1 claim 41 ,3-diol ...

Imageable Polymers

This invention relates to imageable polymers, particularly those comprising poly vinylalcohol and to methods for making them as well as to embolic microspheres comprising the polymers. The microspheres are imageable during embolization procedures and can be loaded with drugs or other therapeutic agents to provide an imageable drug delivery system.

IMPLANTS AND BIODEGRADABLE TISSUE MARKERS

Implantable materials may be used in an iatrogenic site. Applications include radioopaque materials for fiducial marking. 1. A method of making a marker implant in a tissue , comprising filling a iatrogenic site with a flowable synthetic precursor in aqueous medium that set-up to make a covalently-crosslinked hydrogel implant that has a covalently attached radiopaque agent.2. The method of wherein the hydrogel implant has a Hounsfield number of more than about 50.3. The method of wherein the hydrogel implant claim 1 , as placed in the tissue claim 1 , has a volume between 1 and 5 ml.4. The method of wherein the hydrogel is stable claim 1 , having dimensions that do not appreciably change following implantation for a predetermined amount of time claim 1 , and thereafter softens and biodegrades.5. The method of wherein the predetermined amount of time is between 30 and 90 days.6. The method of claim 1 , with the hydrogel being biodegradable to produce only degradation products that are absorbed into the circulatory method and cleared from the body via renal filtration.7. The method of with the hydrogel being hydrolytically biodegradable.8. The method of wherein degradation products of the hydrogel comprise a polyethylene glycol covalently bound to the radioopaque agent claim 1 , with the radioopaque agent comprising iodine.9. The method of wherein the hydrogel is a product of a covalent crosslinking chemical reaction between at least two precursors claim 1 , with one of the precursors comprising a branched polyethylene glycol with at least four arms.10. The method of wherein between 25% and 90% of the arms comprise the radioopaque agent.11. The method of wherein the branched polyethylene glycol has a molecular weight from 5 claim 9 ,000 to 100 claim 9 ,000 Daltons.12. The method of wherein the branched polyethylene glycol has a molecular weight that is more than 20 claim 9 ,000 Daltons and less than 100 claim 9 ,000 Daltons.13. The method of wherein the hydrogel is ...

RADIOPAQUE MONOMERS, POLYMERS, MICROSPHERES, AND METHODS RELATED THERETO

Radiopaque monomers, polymers, and microspheres are disclosed herein. Methods of using the radiopaque monomers, polymers, and microspheres are disclosed herein. Methods of manufacturing radiopaque monomers, polymers, and microspheres are disclosed herein. 3. A polymer comprising polymerized monomers of .4. The polymer of claim 3 , wherein the polymer further comprises at least one of a polymerized acrylamide claim 3 , a polymerized acrylic claim 3 , a polymerized acrylate claim 3 , or a polymerized methacrylate monomer.5. The polymer of claim 3 , wherein the polymer comprises at least one of a polymerized N-[Tris(hydroxymethyl)methyl]acrylamide (CAS No. 13880-05-2) claim 3 , a polymerized N claim 3 ,N′-Methylenebis(acrylamide) (CAS No. 110-26-9) claim 3 , a polymerized diethyl aminoethyl acrylamide claim 3 , a polymerized triethyl aminoethyl acrylamide claim 3 , a polymerized acrylic acid claim 3 , a polymerized methacrylate claim 3 , or a polymerized hydroxyethylmethacrylate.6. The polymer of claim 3 , wherein the polymer further comprises at least one of a cross-linker claim 3 , a gelatin claim 3 , or a coloring agent.7. The polymer of claim 3 , wherein the polymer further comprises an additional radiopaque agent.8. The polymer of claim 3 , wherein the polymer further comprises a magnetic agent.10. The microsphere of claim 9 , wherein the microsphere has a diameter of about 10 microns to about 2000 microns.11. The microsphere of claim 9 , wherein the microsphere swells upon exposure to physiologic conditions.12. The microsphere of claim 9 , wherein the microsphere comprises a therapeutic agent.13. A method of embolization claim 9 , the method comprising injecting the microsphere of into a blood vessel of a patient.14. A method of tracking a microsphere in a patient claim 9 , the method comprising:{'claim-ref': {'@idref': 'CLM-00009', 'claim 9'}, 'introducing the microsphere of into a patient; and'}imaging at least a portion of the patient and determining a ...

RADIOPAQUE POLYMERS

A liquid composition comprising a polymer having pendant groups of the formula I: (I) Wherein X is either a bond or is a linking group having 1 to 8 carbons and optionally 1 to 4 heteroatoms selected from O, N and S; and n is 1 to 4. 2. A liquid composition according to comprising a compound of the formula 1 and a water-miscible solvent.3. A liquid composition according to or wherein n is 1 claim 1 , 2 or 3 claim 1 , preferably 2 or 3.5. A liquid composition according to any preceding claim where X is selected from a bond claim 1 , (C)alkylene claim 1 , (C)oxyalkylene and amino(C)alkylene6. A liquid composition according to any preceding claim where X is a bond.8. A liquid composition according to any preceding claim wherein the polymer is selected from vinylalcohols and copolymers thereof.9. A liquid composition according to wherein the polymer is a polyvinyl alcohol homopolymer or co-polymer.10. A liquid composition according to or wherein the native polymer has a weight average molecular weight of 10 to 250 kDa claim 8 , preferably 20 to 250 kDa.11. A liquid composition according to any preceding claim wherein the polymer is non cross linked.12. A liquid composition according to any preceding claim wherein the polymer is biodegradable13. A liquid composition according to any of to wherein the polymer is non-biodegradable14. A liquid composition according to any preceding claim wherein the polymer comprises 10% or greater Iodine (w/w) of dried polymer.15. A liquid composition according to any of to comprising between 3% and 70% wt/wt polymer dissolved in the solvent.16. A liquid composition according to any preceding claim wherein the polymer precipitates on contact with normal saline at 20° C.17. A liquid composition according to wherein the polymer precipitates on contact with normal saline at 20° C. and the precipitate has a radiodensity of at least 1000 HU18. A liquid composition according to any of to wherein the solvent is a polar aprotic solvent.19. A ...

POLYMERIC TREATMENT COMPOSITIONS

Polymeric compositions are described comprising a biocompatible polymer including a biodegradable linkage to a visualization agent and a non-physiological solution; wherein the biocompatible polymer is soluble in the non-physiological solution and insoluble in a physiological solution. Methods of forming the solutions and polymers are disclosed as well as methods of therapeutic use. 1. An embolic system including:a container including a formulation,wherein the formulation includes a polymer including a biodegradable linkage to a visualization agent wherein the visualization agent is formed from a monomer having at least one aromatic ring and at least one polymerizable moiety, and wherein the polymer is substantially stable and wherein the polymer is soluble in a non-physiological solution and insoluble in a physiological solution.2. The embolic system of claim 1 , wherein the container is a vial or a syringe.3. The embolic system of claim 1 , wherein the biodegradable linkage is Seq. ID 1 claim 1 , Seq. ID 2 claim 1 , Seq. ID 3 claim 1 , Seq. ID 4 claim 1 , Seq. ID 5 claim 1 , Seq. ID 6 claim 1 , Seq. ID 7 claim 1 , Seq. ID 8 claim 1 , Seq. ID 9 claim 1 , Seq. ID 10 claim 1 , Seq. ID 11 claim 1 , Seq. ID 12 claim 1 , Seq. ID 13 claim 1 , an ester claim 1 , a polyester claim 1 , or a combination thereof.4. The embolic system of claim 1 , wherein the monomer having at least one aromatic ring and at least one polymerizable moiety is 2-oxo-2-(1-oxo-1-(1-oxo-1-(2 claim 1 ,4 claim 1 ,6-triiodophenoxy)propan-2-yloxy)propan-2-y-loxy)ethoxy)ethyl acrylate.5. The embolic system of further comprising a second monomer including at least one hydroxyl group.6. The embolic system of claim 5 , wherein the monomer is an acrylate.7. The embolic system of claim 6 , wherein the acrylate is hydroxyethyl methacrylate.8. The embolic system of claim 1 , wherein the non-physiological solution is a water miscible solvent claim 1 , dimethyl formamide or dimethyl sulfoxide.9. The embolic ...

IMPLANTS AND BIODEGRADABLE TISSUE MARKERS

Implantable materials may be used in an iatrogenic site. Applications include radioopaque materials for fiducial marking. 1. A method for radiation therapy comprisingintroducing a hydrogel spacer at a site between a first tissue location and a second tissue location to increase a distance between the first tissue location and the second tissue location, with site being chosen to decrease radiation at the first tissue when the second tissue receives a dose of therapeutic radiation,wherein introducing the hydrogel spacer comprises placing one or more flowable synthetic precursors at the site that undergo a covalent crosslinking reaction to make, at the site, a covalently-crosslinked biodegradable hydrogel implant that has a covalently attached radiopaque agent.2. A method of making a space-occupying implant in a tissue , comprising injecting a tissue site with one or more flowable synthetic precursors in aqueous medium that undergo a covalent cross-linking reaction to make , in the site , a covalently-crosslinked biodegradable hydrogel implant that has a covalently attached radiopaque iodine agent. This application is a continuation of U.S. patent application Ser. No. 15/613,555 filed Jun. 5, 2017 which is a continuation of U.S. patent application Ser. No. 15/066,707 filed Mar. 10, 2016 which is a continuation of U.S. patent application Ser. No. 14/465,202 filed Aug. 21, 2014 which is a divisional of U.S. patent application Ser. No. 13/750,570, filed Jan. 25, 2013 which is a divisional of U.S. patent application Ser. No. 12/968,527, filed Dec. 15, 2010, which claims the benefit of U.S. Provisional Application No. 61/286,450, filed Dec. 15, 2009, each of which are hereby incorporated by reference herein in their entirety.The technical field, in general, relates to stabilizing and visualizing tissue gaps left by surgical removal of cancerous tissues; certain embodiments include polymeric microparticles with attached radioopaque markers.According to the American Cancer ...

IMAGEABLE POLYMERS

This invention relates to imageable polymers, particularly those comprising poly vinylalcohol and to methods for making them as well as to embolic microspheres comprising the polymers. The microspheres are imageable during embolization procedures and can be loaded with drugs or other therapeutic agents to provide an imageable drug delivery system. 137-. (canceled)38. A hydrogel comprising a cross-linked polymer network comprising a polymer having 1 ,2-diol or 1 ,3-diol groups and a radiopaque species covalently bound to the polymer through a cyclic acetal group , the radiopaque species comprising one or more covalently bound radiopaque halogens.39. A hydrogel according to wherein the radiopaque species comprises an iodinated aromatic group.40. A hydrogel according to wherein the radiopaque species comprises a brominated aromatic group.41. A hydrogel according to wherein the hydrogel comprises polyvinyl alcohol (PVA) in which the PVA comprises pendent groups formed from the acetalisation of PVA with N-acryloyl-aminoacetaldehyde dimethylacetal and which is cross-linked with 2-acrylamido-2-methylpropanesulfonic acid (PVA-AMPS).42. A hydrogel according to wherein the one or more covalently bound radiopaque halogens comprise bromine.43. A hydrogel according to wherein the one or more covalently bound radiopaque halogens comprise iodine.44. A hydrogel according to wherein the radiopaque species comprises an iodinated phenyl group.45. A hydrogel according to wherein the hydrogel comprises greater than 10% iodine by dry weight.46. A hydrogel according to wherein the hydrogel is in the form of microparticles or microspheres.47. A hydrogel according to wherein the hydrogel is in the form of microspheres with a mean diameter size range of from 10 to 2000 μm.48. A hydrogel according to in the form of microspheres or microparticles having a mean radiopacity of 500HU or greater.49. A hydrogel according to wherein the hydrogel has a net charge at physiological pH.52. A composition ...

Polymeric treatment compositions

Polymeric compositions are described comprising a biocompatible polymer including a biodegradable linkage to a visualization agent and a non-physiological pH solution; wherein the biocompatible polymer is soluble in the non-physiological pH solution and insoluble at a physiological pH. Methods of forming the solutions and polymers are disclosed as well as methods of therapeutic use.

ECHOLUCENT IMPLANTS

Echolucent implantable materials may delivered to a selected placement site and biodegrade after a certain period of time. Applications include delivery of therapeutic agents to the placement site. 1. A method for treating a patient comprisingdelivering a pharmaceutically acceptable implant through an applicator into the patient at a selected placement site, the implant comprising a flowable, hydrolytically biodegradable polymer composition, an osmotic agent, and a therapeutic agent, wherein the flowable, hydrolytically biodegradable polymer composition comprises a collection of covalently-crosslinked hydrolytically biodegradable hydrogel particles, a hydrogel precursor composition that reacts to form covalent bonds at physiological conditions with the product being covalently-crosslinked hydrolytically biodegradable hydrogel particles, or a combination thereof, wherein the implant at the selected placement site is echolucent, and wherein the therapeutic agent is released from the hydrogel particles at the placement site.2. The method for treating a patient of further comprising monitoring the delivering of the implant to the placement site with ultrasound.3. The method for treating a patient of wherein the implant further comprises a pharmaceutically acceptable fluid and wherein the implant is delivered to the placement site as a slurry.4. The method for treating a patient of wherein the applicator comprises a syringe claim 1 , a catheter claim 1 , a needle claim 1 , or combinations thereof.5. The method for treating a patient of wherein the applicator comprises a double barreled syringe.6. The method for treating a patient of wherein the applicator comprises a syringe connected to a needle claim 1 , and the delivering of the implant comprises injecting the implant through the needle into the placement site.7. The method for treating a patient of wherein the hydrogel particles have an average diameter from about 10 microns to about 500 microns.8. The method for ...

ECHOLUCENT IMPLANTS

Echolucent implantable compositions are described. Applications include materials for delivering of therapeutic agents to a tissue at a placement site. 1. A pharmaceutically acceptable implant composition comprising:a collection of covalently-crosslinked hydrolytically biodegradable hydrogel particles, a therapeutic agent, and an osmotic agent, wherein the pharmaceutically acceptable implant composition is echolucent.2. The pharmaceutically acceptable implant composition of further comprising a radiopaque agent.3. The pharmaceutically acceptable implant composition of wherein the radiopaque agent is covalently attached to a plurality of the hydrogel particles in the collection.4. The pharmaceutically acceptable implant composition of wherein the collection comprises hydrogel particles having an average diameter from about 10 microns to about 500 microns.5. The pharmaceutically acceptable implant composition of wherein the collection comprises hydrogel particles having an average diameter from about 125 microns to about 500 microns.6. The pharmaceutically acceptable implant composition of further comprising an ultrasound contrast agent.7. The pharmaceutically acceptable implant composition of wherein the therapeutic agent comprises a pain reliever claim 1 , an anesthetic claim 1 , a steroid claim 1 , a chemotherapeutic agent claim 1 , or combinations thereof.8. The pharmaceutically acceptable implant composition of wherein a volume of the pharmaceutically acceptable implant composition increases no more than 50% upon exposure to an in vitro physiological saline solution or an in vivo environment in a tissue.9. The pharmaceutically acceptable implant composition of wherein the collection has a time for complete degradation from about 7 days to about 180 days in an in vivo environment in a tissue.10. The pharmaceutically acceptable implant composition of wherein the collection is hydrolytically biodegradable in vivo to produce degradation products that are absorbed ...

ECHOLUCENT IMPLANTS

Echolucent implantable compositions are described. Applications include materials for delivering of therapeutic agents to a tissue at a placement site. 1. A pharmaceutically acceptable implant composition comprising:a hydrogel precursor composition, a therapeutic agent, and a pharmaceutically acceptable fluid, wherein the hydrogel precursor composition comprises a first precursor compound with a plurality of first functional groups and a second precursor compound with a plurality of second functional groups, wherein the first functional groups are capable of forming covalent bonds with the second functional groups at physiological conditions, and wherein the pharmaceutically acceptable implant composition is echolucent following reaction of the hydrogel precursor composition to form a collection of covalently-cross-linked, hydrolytically biodegradable hydrogel particles.2. The pharmaceutically acceptable implant composition of further comprising a radiopaque agent.3. The pharmaceutically acceptable implant composition of wherein the radiopaque agent is covalently attached to the hydrogel precursor composition.4. The pharmaceutically acceptable implant composition of wherein the collection comprises hydrogel particles having an average diameter from about 10 microns to about 500 microns.5. The pharmaceutically acceptable implant composition of wherein the collection comprises hydrogel particles having an average diameter from about 125 microns to about 500 microns.6. The pharmaceutically acceptable implant composition of further comprising an ultrasound contrast agent.7. The pharmaceutically acceptable implant composition of wherein the therapeutic agent comprises an anesthetic claim 1 , a steroid claim 1 , a chemotherapeutic agent claim 1 , or combinations thereof.8. The pharmaceutically acceptable implant composition of wherein a volume of the pharmaceutically acceptable implant composition increases no more than 50% in an in vitro physiological saline solution or ...

POLYMERIC TREATMENT COMPOSITIONS

Polymeric compositions are described comprising a biocompatible polymer including a biodegradable linkage to a visualization agent and a non-physiological pH solution; wherein the biocompatible polymer is soluble in the non-physiological pH solution and insoluble at a physiological pH. Methods of forming the solutions and polymers are disclosed as well as methods of therapeutic use. 1. A polymer including:a biodegradable linkage to a visualization agent having at least one aromatic ring,wherein the polymer is substantially stable and wherein the polymer is soluble in a non-physiological solution and insoluble in a physiological solution.2. The polymer of claim 1 , wherein the biodegradable linkage is Seq. ID 1 claim 1 , Seq. ID 2 claim 1 , Seq. ID 3 claim 1 , Seq. ID 4 claim 1 , Seq. ID 5 claim 1 , Seq. ID 6 claim 1 , Seq. ID 7 claim 1 , Seq. ID 8 claim 1 , Seq. ID 9 claim 1 , Seq. ID 10 claim 1 , Seq. ID 11 claim 1 , Seq. ID 12 claim 1 , or Seq. ID 13.3. The polymer of claim 1 , wherein the biodegradable linkage is an ester or a polyester.4. The polymer of claim 1 , wherein a monomer included in the polymer is 2-oxo-2-(1-oxo-1-(1-oxo-1-(2 claim 1 ,4 claim 1 ,6-triiodophenoxy)propan-2-yloxy)propan-2-yloxy)ethoxy)ethyl acrylate.5. The polymer of including a monomer including at least one hydroxyl group.6. The polymer of claim 5 , wherein the monomer is an acrylate.7. The polymer of claim 6 , wherein the acrylate is hydroxyethyl methacrylate.8. The polymer of claim 1 , wherein the non-physiological solution is dimethyl formamide.9. The polymer of claim 1 , wherein the non-physiological solution is dimethyl sulfoxide.10. The polymer of including a reaction product of between about 75% and about 98% 2-oxo-2-(1-oxo-1-(1-oxo-1-(2 claim 1 ,4 claim 1 ,6-triiodophenoxy)propan-2-yloxy)propan-2-yloxy)ethoxy)ethyl acrylate claim 1 , between about 2% and about 25% hydroxyethyl methacrylate claim 1 , and less than 1% azobisisobutyronitrile.11. The polymer of including a reaction ...

RADIOPAQUE MONOMERS, POLYMERS, MICROSPHERES, AND METHODS RELATED THERETO

Radiopaque monomers, polymers, and microspheres are disclosed herein. Methods of using the radiopaque monomers, polymers, and microspheres are disclosed herein. Methods of manufacturing radiopaque monomers, polymers, and microspheres are disclosed herein. 3. The method of claim 1 , wherein the vinyl moiety of the first monomer of Formula I is incorporated into the backbone of the polymer.4. The method of claim 1 , wherein the solution further comprises a second monomer selected from an acrylamide claim 1 , an acrylic claim 1 , an acrylate claim 1 , or a methacrylate monomer.5. The method of claim 4 , wherein the second monomer comprises an N-[Tris(hydroxymethyl)methyl]acrylamide claim 4 , N claim 4 ,N′-Methylenebis(acrylamide) claim 4 , diethyl aminoethyl acrylamide claim 4 , triethyl aminoethyl acrylamide claim 4 , acrylic acid claim 4 , methacrylate claim 4 , or hydroxyethylmethacrylate.6. The method of claim 1 , wherein the solution further comprises an acrylamide monomer.7. The method of claim 6 , wherein the solution comprises at least one of N-[Tris(hydroxymethyl)methyl]acrylamide or N claim 6 ,N′-Methylenebis(acrylamide).8. The method of claim 1 , further comprising:cross-linking the polymer.9. The method of claim 1 , wherein the microsphere further comprises an additional radiopaque agent.10. The method of claim 1 , wherein the microsphere further comprises a magnetic agent.11. The method of claim 1 , wherein the microsphere further comprise a therapeutic agent.12. The method of claim 1 , wherein the microsphere is non-resorbable within a body of a patient.15. The method of claim 13 , wherein the second monomer is selected from at least one of N-[Tris(hydroxymethyl)methyl]acrylamide claim 13 , N claim 13 ,N′-Methylenebis(acrylamide) claim 13 , diethyl aminoethyl acrylamide claim 13 , triethyl aminoethyl acrylamide claim 13 , acrylic acid claim 13 , methacrylate claim 13 , or hydroxyethylmethacrylate.16. The method of claim 13 , wherein the second monomer ...

RADIOPAQUE POLYMERS

Radiopaque hydrogels, in particular radiopaque hydrogel microspheres, comprising a polymer having 1,2-dil or 1,3-diol groups acetalized with radiopaque species. 1. A hydrogel in the form of microspheres comprising a cross-linked polymer network that comprises polyvinyl alcohol (PVA) or a copolymer of PVA and a radiopaque species comprising one or more covalently bound iodines that are coupled to the PVA or copolymer of PVA through a cyclic acetal group and that provides the microspheres with greater than 15 mg of iodine per ml of microspheres fully hydrated in normal saline as a packed volume.2. The hydrogel of claim 1 , wherein the radiopaque species provides the microspheres with greater than 50 mg of iodine per ml of microspheres fully hydrated in normal saline as a packed volume.3. The hydrogel of claim 1 , wherein the radiopaque species provides the microspheres with greater than 100 mg of iodine per ml of microspheres fully hydrated in normal saline as a packed volume.4. The hydrogel of claim 1 , wherein the radiopaque species comprises an iodinated aromatic group.5. The hydrogel of claim 1 , wherein the radiopaque species comprises an iodinated phenyl group.6. The hydrogel of claim 1 , wherein the microspheres have a mean diameter size range of from 10 to 2000 μm.7. The hydrogel of claim 1 , wherein the microspheres have a mean radiopacity of 500 HU or greater.8. The hydrogel of claim 1 , wherein the hydrogel has a net charge at physiological pH.9. A method of treatment in which a hydrogel according is administered into a blood vessel of a patient to embolize said blood vessel.10. The method of claim 9 , wherein the blood vessel is associated with a solid tumor.11. The method of claim 10 , wherein the solid tumor is hepatocellular carcinoma.12. A composition comprising (a) hydrogel in the form of microspheres comprising a cross-linked polymer network that comprises polyvinyl alcohol (PVA) or a copolymer of PVA and a radiopaque species comprising one or more ...

RADIOPAQUE POLYMERS

A hydrophilic polymer comprising pendent groups of the formula I: Wherein: W is independently selected from —OH, —COOH, —SOH, —OPOH, —O—(Calkyl), —O—(Calkyl)OH, —O—(Calkyl)R, —O—(CHO)R—(C═O)—O—Calkyl and —O—(C═O)Calkyl; or a group —BZ; wherein —OH, COOH, O—POH and SOH maybe in the form of a pharmaceutically acceptable salt; wherein: B is a bond, or a straight branched alkanediyl, oxyalkylene, alkylene oxaalkylene, or alkylene (oligooxalkylene) group, optionally containing one or more fluorine substituents; and Z is an ammonium, phosphonium, or sulphonium phosphate or phosphonate ester zwitterionic group; X is either a bond or a linking group having 1 to 8 carbons and optionally 1 to 4 heteroatoms selected from O, N and S; G is a coupling group through which the group of the formula I is coupled to the polymer and is selected from ether, ester, amide, carbonate, carbamate, 1,3 dioxolone, and 1,3 dioxane; Ris H or Calkyl; Ris —COOH, —SOH, or —OPOHq is an integer from to 4; n is an integer from 1 to 4; p is an integer from 1 to 3; and n+p is from 2 to 5; and wherein —COOH, —OPOHand —SOH as well as phenolic —OH maybe in the form of a pharmaceutically acceptable salt. 2. A polymer according to which is a polyhydroxylated polymer and G is selected from ether claim 1 , ester claim 1 , carbonate claim 1 , carbamate claim 1 , 1 claim 1 ,3 dioxolone claim 1 , and 1 claim 1 ,3 dioxane;3. A polymer according to which is a polycarboxylated polymer and G is selected from ester and amide.4. A polymer according to or which is a polymer or co-polymer of polyvinyl alcohol and wherein the groups of the formula I are coupled through hydroxyl groups of the polyvinyl alcohol.5. A polymer according to or which is a homopolymer or co-polymer of PVA and wherein the groups of the formula I are coupled through hydroxyl groups of the polyvinyl alcohol.7. A polymer of any preceding claim in which n is two or three.8. A polymer according to any preceding claim in which the phenyl ring of the ...

EMBOLIC COMPOSITIONS

Described herein are compositions comprising, a polymer; a non-physiological solution; and a visualization agent; wherein the polymer is soluble in the non-physiological solution and insoluble at physiological conditions. Methods of preparing the compositions are disclosed as well as methods of using these compositions to treat vascular conditions. 1. A method of delivering a composition comprising:injecting a composition, including a biocompatible polymer, a solvent, and a visualization agent wherein the biocompatible polymer is soluble in the solvent and insoluble at physiological conditions, and wherein the composition has a viscosity of less than about 15 centistokes, through a delivery device into a location with the physiological condition.2. The method of claim 1 , wherein the visualization agent is integrated into or associated with the biocompatible polymer.3. The method of claim 2 , wherein the visualization agent is triiodophenol-lactide-glycolide (TIP).4. The method of claim 1 , wherein the physiological conditions include contact with a physiological fluid including blood claim 1 , urine claim 1 , saliva claim 1 , mucous claim 1 , vaginal fluid claim 1 , seminal fluid claim 1 , cerebral spinal fluid claim 1 , sweat claim 1 , plasma claim 1 , bile claim 1 , stomach acid claim 1 , intestinal fluids claim 1 , or a combination thereof.5. The method of claim 4 , wherein the physiological fluid has a pH of between about 7.0 and about 7.8.6. The method of claim 1 , wherein the solvent is a water miscible organic solvent.7. The method of claim 1 , wherein the biocompatible polymer comprises an amine and the amine includes an amino group which is about 90% positively charged at a pH of 5 and about 10% positively charged at a pH of 7.8. The method of claim 1 , wherein the biocompatible polymer includes hydroxyethylmethacrylate (HEMA) claim 1 , lactide claim 1 , glycolide claim 1 , polyvinyl pyridine (PVP) claim 1 , 1-vinylimidazole claim 1 , aminoethyl ...

IMPLANTS AND BIODEGRADABLE TISSUE MARKERS

Implantable materials may be used in an iatrogenic site. Applications include radioopaque materials for fiducial marking.

COMPOSITIONS FOR NANOCONFINEMENT INDUCED CONTRAST ENHANCEMENT AND METHODS OF MAKING AND USING THEREOF

Multivalent CT or MR contrast agents and methods of making and using thereof are described herein. The agents contain a moiety, such as a polymer, that provides multivalent attachment of CT or MR contrast agents. Examples include, but are not limited to, multivalent linear polymers, branched polymers, or hyperbranched polymers, such as dendrimers, and combinations thereof. The dendrimer is functionalized with one or more high Z-elements, such as iodine. The high Z-elements can be covalently or non-covalently bound to the dendrimer. The dendrimers are confined in order to enhance CT contrast. In some embodiments, the moiety is confined by encapsulating the dendrimers in a material to form particles, such as nanoparticles. In other embodiments, the dendrimer is confined by conjugating the moiety to a material, such as a polymer, which forms a gel upon contact with bodily fluids.

RADIOPAQUE POLYMERS

Radiopaque hydrogels, in particular radiopaque hydrogel microspheres, comprising a polymer having 1,2-dil or 1,3-diol groups acetalized with radiopaque species. 135-. (canceled)37. A crosslinked hydrogel polymer according to wherein X is a group of the formula ZQ;wherein:{'sub': 1-6', '1-6', '1-6, 'Z is a linking group or is absent and wherein if Z is present, then Z is Calkylene, Calkoxylene or Calkoxyalkylene; and'}{'sub': 5', '12, 'Q is a Cto Caryl, heteroaryl or cycloalkyl group.'}38. A crosslinked hydrogel polymer according to claim 37 , wherein Q is a Cto Caryl group.39. A crosslinked hydrogel polymer according to claim 37 , wherein Q is an iodinated phenyl group.40. A cross linked hydrogel polymer according to claim 37 , wherein Z is absent.41. A cross linked hydrogel polymer according to claim 37 , wherein Z is a methylene or ethylene group or is a group —(CH)—O—(CH2)— wherein q is 0 claim 37 , 1 or 2 and p is 1 or 2.42. A crosslinked hydrogel polymer according to wherein claim 37 , Z is —(CH)O(CH)— claim 37 , —CHOCH— claim 37 , —(CH)O— claim 37 , —CHO—.43. A crosslinked hydrogel polymer according to wherein the polymer has a net charge at pH 7.4.44. A crosslinked hydrogel polymer according to claim 36 , wherein the polymer is in the form of microparticles or microspheres.45. A crosslinked hydrogel polymer according to claim 43 , wherein the polymer is in the form of microspheres with a mean diameter size range of from 10 to 2000 μm.46. A crosslinked hydrogel polymer according to wherein the polymer comprises greater than 10% iodine by dry weight.47. A crosslinked hydrogel polymer according to wherein the polymer comprises greater than 30% iodine by dry weight.48. A crosslinked hydrogel polymer according to claim 44 , wherein the polymer comprises greater than 15 mg of iodine per ml of microspheres fully hydrated in normal saline.49. A crosslinked hydrogel polymer according to claim 48 , wherein the polymer comprises greater than 50 mg of iodine per ml of ...

IMAGEABLE POLYMERS

This invention relates to imageable polymers, particularly those comprising poly vinylalcohol and to methods for making them as well as to embolic microspheres comprising the polymers. The microspheres are imageable during embolization procedures and can be loaded with drugs or other therapeutic agents to provide an imageable drug delivery system. 137-. (canceled)38. Hydrogel polymer microspheres wherein the hydrogel polymer comprises: a polyvinyl alcohol (PVA) backbone comprising 1 ,3 diol groups and further comprises at least two pendant groups having cross-linkable ethylenically unsaturated functional groups which are cross linked by a vinylic co-monomer;wherein at least a portion of the 1,3 diol groups of the PVA backbone are acetalised with a radiopaque species which is coupled to the hydrogel polymer through a cyclic acetal group, the radiopaque species comprising one or more covalently bound iodines and wherein the hydrogel polymer microspheres comprise at least 52 mg of iodine per milliliter of fully hydrated microspheres when measured as a packed volume.39. Hydrogel polymer microspheres according to claim 38 , wherein the pendant chains comprising cross-linkable ethylenically unsaturated functional groups are attached to 1 claim 38 ,3-diol groups of the PVA backbone via cyclic acetal linkages.40. Hydrogel polymer microspheres according to claim 38 , wherein the vinylic co-monomer is 2-acrylamido-2-methylpropanesulfonic acid.41. Hydrogel polymer microspheres according to claim 38 , wherein the ethylenically unsaturated functional groups are acrylate groups.42. Hydrogel polymer microspheres according to claim 38 , wherein the radiopaque species comprises an iodinated phenyl group.44. Hydrogel polymer microspheres according to claim 43 , wherein claim 43 , Z is (i) a methylene or ethylene group or is (ii) a group —(CH)—O—(CH)— wherein q is 0 claim 43 , 1 or 2 and p is 1 or 2 or is (iii) absent.45. Hydrogel polymer microspheres according to claim 43 , wherein ...

IMPLANTS AND BIODEGRADABLE FIDUCIAL MARKERS

Implantable materials may be used in an iatrogenic site. Applications include radioopaque materials for fiducial marking. 1. A method of treating a patient comprisingplacing a collection of pharmaceutically acceptable, covalently-crosslinked hydrogel particles into a tissue of the patient, the collection comprising a plurality of the particles having a covalently attached radiopaque agent, with the radiopaque agent being present in the collection at a concentration of at least about 0.1% w/w.2. The method of wherein the collection has a Hounsfield number of more than about 50.3. The method of wherein the collection claim 1 , as placed in the patient claim 1 , has a volume between 5 and 40 ml.4. The method of wherein the collection is stable claim 1 , having dimensions that do not appreciably change following implantation for a predetermined amount of time claim 1 , and thereafter softens and biodegrades.5. The method of wherein the predetermined amount of time is between 30 and 90 days.6. The method of with the hydrogel particles comprising the covalently attached radiopaque agent being a first set of particles claim 1 , and further comprising a second set of particles comprising particles free of a covalently-bound radiopaque agent.7. The method of with the collection further comprising a non-covalently bound radiopaque agent.8. The method of wherein the hydrogel particles are spheroidal with a maximum diameter of between about 20 to about 200 microns.9. The method of claim 1 , with the hydrogel particles being biodegradable to produce only degradation products that are absorbed into the circulatory method and cleared from the body via renal filtration.10. The method of with the hydrogel particles being hydrolytically biodegradable.11. The method of wherein the hydrogel particles claim 10 , before hydrolysis claim 10 , have a total swellability in physiological solution of no more than about 30% by volume.12. The method of wherein degradation products of the ...

IODINE-BASED PARTICLES

Described herein are iodine-based particles which can be used as contrast agents for x-ray radiology. Also described herein are methods, software modules and hardware modules for imaging iodine-based particles. 1. An iodine nanoparticle which is a reaction product of functionalized triiodobenzene , linking monomers , and biocompatible polymers;wherein said functionalized triiodobenzene, said linking monomers, and said biocompatible polymers are covalently cross-linked resulting in the structure of said nanoparticle being non-dendritic, non-uniform, and non-linear;wherein said nanoparticle has a polydispersity index of about 0.5 or less;wherein said nanoparticle has sufficient iodine density to be imaged by an imaging device following administration to a subject; andwherein said nanoparticle provides for an extended blood half-life.2. The nanoparticle according to wherein said functionalized triiodobenzene is functionalized 1 claim 1 ,3 claim 1 ,5-triiodobenzene or functionalized 2 claim 1 ,4 claim 1 ,6-triiodobenzene.4. The iodine nanoparticle according to wherein said functionalized triiodobenzene is 2 claim 1 ,4 claim 1 ,6-triiodophenol claim 1 , 2-(2 claim 1 ,4 claim 1 ,6-triiodophenoxy)ethanol claim 1 , 2-(2-bromoethoxy)1 claim 1 ,3 claim 1 ,5-triiodobenzene claim 1 , (2 claim 1 ,4 claim 1 ,6-triiodophenoxy)acetamide claim 1 , 2-(2 claim 1 ,4 claim 1 ,6-triiodophenoxy)ethanesulfonic acid claim 1 , 3-hydroxy-2 claim 1 ,4 claim 1 ,6-triiodobenzoic acid claim 1 , 3-amino-2 claim 1 ,4 claim 1 ,6-triiodobenzoic acid claim 1 , methyl 2-(2 claim 1 ,4 claim 1 ,6-triiodophenoxy)butyrate claim 1 , (2-(2 claim 1 ,4 claim 1 ,6-triiodophenoxy)-ethyl)trimethylammonium methanesulfonate claim 1 , 5-amino-2 claim 1 ,4 claim 1 ,6-triiodoisophthalic acid claim 1 , α-ethyl-3-hydroxy-2 claim 1 ,4 claim 1 ,6-triiodohydrocinnamic acid claim 1 , iopanoic acid claim 1 , 7-(3-amino-2 claim 1 ,4 claim 1 ,6-triiodophenyl)heptanoic acid claim 1 , 7-(3-amino-2 claim 1 ,4 claim 1 ,6- ...

BIODEGRADABLE POLYESTER- AND POLY(ESTER AMIDE) BASED X-RAY IMAGING AGENTS

Biodegradable, radio-opaque polyesters and poly(ester amides) are described herein. The polyesters contain a plurality of radio-opaque agents or radio-opaque agent-containing moieties that are covalently bound along or from the polymer backbone. The agents/moieties may be bound to the termini of the polymer provided they are bound within the polyester backbone as well. The polyester can be aliphatic or aromatic. The polyester and poly(ester amide) is substituted with a plurality of radio-opaque graft agents or prepared from an appropriate radio-opaque monomer agent. The materials can be used for any application where a radio-opaque material is desired or necessary. The materials can be used to form, in whole or in part, a medical device, or coating thereon or therein. 1. A biodegradable , radio-opaque polymer , the polymer comprising a polyester or poly(ester amide) comprising a plurality of radio-opaque agents covalently bound to the polyester or poly(ester amide) backbone.3. The polymer of claim 2 , wherein the molecular weight of the polymer is from about 300 Daltons to about 250 claim 2 ,000 Daltons.4. The polymer of claim 3 , wherein the degree of substitution is at least about 1% claim 3 , 2% claim 3 , 3% claim 3 , 4% claim 3 , 5% claim 3 , 8% claim 3 , 10% claim 3 , 15% claim 3 , 20% claim 3 , 25% claim 3 , 30% claim 3 , 35% claim 3 , 40% claim 3 , 45% claim 3 , 50% claim 3 , 55% claim 3 , 60% claim 3 , 65% claim 3 , 70% claim 3 , 75% claim 3 , 80% claim 3 , 85% claim 3 , 90% claim 3 , 95% claim 3 , or 99%.5. The polymer of claim 4 , wherein the degree of substitution is 100%.6. The polymer of claim 1 , wherein the radio-opaque agent is covalently bound directly to the polyester or poly(ester amide) backbone.7. The polymer of claim 1 , wherein the radio-opaque agent is covalently bound to the polyester poly(ester amide) backbone via a spacer or linker.8. The polymer of claim 1 , wherein the radio-opaque agent is iodine or an iodine-containing moiety.9. The ...

BIOCOMPATIBLE IODINATED DIPHENOL MONOMERS AND POLYMERS

Disclosed are monomeric compounds which may be polymerized to form novel biodegradable and bioresorbable polymers and co-polymers. These polymers and co-polymers, while not limited thereto, may be adapted for radiopacity and are useful for medical device applications and controlled release therapeutic formulations. 2. The compound of wherein at least two of the X are I.4. The compound of claim 3 , wherein n is an integer from 1 to 6.5. The compound of claim 1 , wherein each X is independently H or I.6. The compound of claim 5 , wherein n is an integer from 1 to 6. This application is a Divisional application of U.S. Nonprovisional application Ser. No. 14/983,801, filed Dec. 30, 2015 which is a continuation of PCT/IB2015/059967, filed Dec. 23, 2015, which claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Applications No. 62/138,572 filed on Mar. 26, 2015 and 62/096,420 filed on Dec. 23, 2014, all of which are hereby incorporated by reference in their entirety for all purposes.The present invention relates to new classes of monomeric compounds, which may be polymerized to form novel biodegradable and bioresorbable polymers and co-polymers. These polymers and co-polymers, while not limited thereto, may be adapted for radio-opacity and are useful for medical device applications and controlled release therapeutic formulations.The present invention thus also relates to new biocompatible polymers suitable for use in implantable medical devices and monomers for such polymers. In particular, the present invention relates to polymers polymerized from monomer analogs of compounds that naturally occur in the human body and that contribute advantageous synthesis, processing and material properties to the polymers prepared therefrom.Diphenols are monomeric starting materials for polycarbonates, polyiminocarbonates, polyarylates, polyurethanes and the like. U.S. Pat. No. 5,099,060 discloses diphenolic monomers based on 3-(4-hydroxyphenyl) propionic acid and L- ...

EMBOLIC COMPOSITIONS

Described herein are compositions comprising, a polymer; a non-physiological solution; and a visualization agent; wherein the polymer is soluble in the non-physiological solution and insoluble at physiological conditions. Methods of preparing the compositions are disclosed as well as methods of using these compositions to treat vascular conditions. 1. A composition comprising:a biocompatible polymer;a solvent; anda visualization agent;wherein the biocompatible polymer is soluble in the solvent and insoluble at physiological conditions, and wherein the composition has a viscosity of less than about 15 centistokes.2. The composition of claim 1 , wherein the visualization agent is integrated into or associated with the biocompatible polymer.3. The composition of claim 2 , wherein the visualization agent is triiodophenol-lactide-glycolide (TIP).4. The composition of claim 1 , wherein the physiological conditions include contact with a physiological fluid including blood claim 1 , urine claim 1 , saliva claim 1 , mucous claim 1 , vaginal fluid claim 1 , seminal fluid claim 1 , cerebral spinal fluid claim 1 , sweat claim 1 , plasma claim 1 , bile claim 1 , stomach acid claim 1 , intestinal fluids claim 1 , or a combination thereof.5. The composition of claim 4 , wherein the physiological fluid has a pH of about 7.0.6. The composition of claim 4 , wherein the physiological fluid has a pH of between about 7.0 and about 7.8.7. The composition of claim 1 , wherein the solvent is a water miscible organic solvent.8. The composition of claim 1 , wherein the biocompatible polymer comprises an amine and the amine includes an amino group which is about 90% positively charged at a pH of 5 and about 10% positively charged at a pH of 7.9. The composition of claim 1 , wherein the biocompatible polymer includes hydroxyethylmethacrylate (HEMA) claim 1 , lactide claim 1 , glycolide claim 1 , polyvinyl pyridine (PVP) claim 1 , 1-vinylimidazole claim 1 , aminoethyl methacrylate (AEMA) claim ...

IMAGEABLE EMBOLIC MICROSPHERE

This invention concerns imageable, radiopaque embolic beads, which are particularly useful for monitoring embolization procedures. The beads comprise iodine containing compounds which are covalently incorporated into the polymer network of a preformed hydrogel bead. The beads are prepared by activating pre-formed hydrogel beads towards nucleophilic attack and then covalently attaching iodinated compounds into the polymer network. The radiopaque beads may be loaded with chemotherapeutic agents and used in methods of embolizing hyperplastic tissue or solid tumors.

polymers

不可降解的栓塞微球

本发明涉及包含交联基质的不可生物降解的栓塞微球，该基质基于至少以下：a)从20％至95％的亲水性单体；b)从1％至15％的不可生物降解的亲水性交联单体；以及c)从1.5％至少于6％的转移剂，该转移剂选自烷基卤化物和环脂肪族硫醇或脂肪族硫醇，特别地这些烷基卤化物和环脂肪族硫醇或脂肪族硫醇具有2至24个碳原子，并且任选地具有选自氨基、羟基和羧基基团的另一种官能团。本发明进一步涉及包含与有利地用于肠胃外施用的药学上可接受的媒介物连同的根据本发明的不可生物降解的栓塞微球的药物组合物。本发明进一步涉及试剂盒，该试剂盒包含药物组合物以及至少一种注射手段，该药物组合物包含与用于肠胃外施用的药学上可接受的媒介物结合的根据本发明的不可生物降解的栓塞微球。

Polymers with crystallising side chains for medical use

FIELD: chemistry. ^ SUBSTANCE: proposed is an X-ray contrast polymer containing a backbone chain which is a repeating unit of one of five proposed formulae; several crystallising side chains containing 20-30 carbon atoms, and several heavy atoms bonded to that polymer and present in such an amount which is effective for detecting an X-ray contrast polymer, where at least one of the heavy atoms is iodine or bromine. Also proposed are versions of the method of producing the said polymer, medical devices containing the said polymer and a method for partially clogging the body cavity for therapeutic purposes. ^ EFFECT: obtaining novel X-ray contrast polymers with crystallising side chains, which can be fluid at temperatures above the body temperature of mammals, and solidify when cooled to body temperature. ^ 74 cl, 6 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 2 383 558 (13) C2 (51) МПК C08G C08G C08G A61K 64/12 65/40 63/685 49/04 (2006.01) (2006.01) (2006.01) (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ, ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (21), (22) Заявка: 2007104489/04, 07.07.2005 (24) Дата начала отсчета срока действия патента: 07.07.2005 (73) Патентообладатель(и): РЕВА МЕДИКАЛ, ИНК. (US) (43) Дата публикации заявки: 27.08.2008 C 2 2 3 8 3 5 5 8 C 2 R U (56) Список документов, цитированных в отчете о поиске: WO 9924391 А1, 20.05.1999. RU 2147592 C1, 20.04.2000. US 5670602 A, 23.09.1997. US 4980449 A, 25.12.1990. US 6238687 B1, 29.05.2001. US 2004086461 A1, 06.05.2004. Kimberly A. Hooper, Joachim Kohn «Diphenolic Monomers Derived from the Natural Amino Acid &-L-Tyrosine: An Evaluation of Peptide Coupling Techniques». Journal of Bioactive and (см. прод.) (85) Дата перевода заявки PCT на национальную фазу: 08.02.2007 (86) Заявка PCT: US 2005/024289 (07.07.2005) (87) Публикация PCT: WO 2006/014596 (09.02.2006) Адрес для переписки: 125502, Москва, ул. Лавочкина, 50-1, кв.24, пат.пов. Н.Л.Цетович (54) ПОЛИМЕРЫ С КРИСТАЛЛИЗУЮЩИМИСЯ ...

生物相容性的碘化二酚单体和聚合物

本发明公开了单体化合物，其可以被聚合以形成新的生物可降解的和生物可再吸收的聚合物和共聚物。虽然不限于此，但这些聚合物和共聚物，可以适用于辐射不透性，并且可用于医疗器械应用以及控制释放的治疗制剂。

一种具有抗菌活性的医用可降解聚氨酯及其用途

本发明公开了一种具有抗菌活性的医用可降解聚氨酯及其用途，具体涉及一种含有壳聚糖或其衍生物作的医用可降解聚氨酯、其制备方法和在植介入生物材料方面的应用，可以根据再生医学以及植入体内的医疗器械的需要，设计合成不同分子量和降解性能的具有抗菌活性的医用可降解聚氨酯。

生物相容性的碘化二酚单体和聚合物

本发明公开了单体化合物，其可以被聚合以形成新的生物可降解的和生物可再吸收的聚合物和共聚物。虽然不限于此，但这些聚合物和共聚物，可以适用于辐射不透性，并且可用于医疗器械应用以及控制释放的治疗制剂。

Gel composition for radiation therapy under visual control

FIELD: medicine; pharmaceuticals. SUBSTANCE: group of inventions relates to the field of chemical-pharmaceutical industry, more specifically to the contrast composition for topical administration, exhibiting X-ray contrast properties, which contains: a gelling agent - sucrose acetate isobutyrate, a radiopaque agent - 6,6'-(2,4,6-triiodophenoxy)acetoxy-iso-butyric saccharose and a biologically compatible organic solvent - ethanol; as well as to a set for recording an X-ray image consisting of said contrast composition, a syringe and a needle for injecting a contrast composition into a body adapted to be placed on an open end of the syringe. Also disclosed is a method of detecting an x-ray image of a mammalian body and a method for combined radiotherapy and X-ray imaging of a target tissue in a mammal, providing for stage of introduction of specified contrast composition into respectively predetermined place or predetermined target tissue in mammalian body. EFFECT: group of inventions provides a low viscosity composition which is easily administered parenterally and demonstrates good visualization. 20 cl, 8 ex, 4 tbl, 18 dwg РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 703 303 C2 (51) МПК A61K 49/04 (2006.01) A61K 49/12 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК A61K 49/04 (2013.01); A61K 49/0438 (2013.01); A61K 49/0442 (2013.01); A61K 49/0452 (2013.01) (21)(22) Заявка: 2015154681, 23.05.2014 (24) Дата начала отсчета срока действия патента: Дата регистрации: Приоритет(ы): (30) Конвенционный приоритет: 24.05.2013 SE 1350637-3 (43) Дата публикации заявки: 30.06.2017 Бюл. № 19 (45) Опубликовано: 16.10.2019 Бюл. № 29 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 24.12.2015 EP 2014/060673 (23.05.2014) (87) Публикация заявки PCT: R U 2 7 0 3 3 0 3 WO 2014/187962 (27.11.2014) Адрес для переписки: 197101, Санкт-Петербург, а/я 128, "АРСПАТЕНТ", К.В. Осипов (54) СОСТАВ ГЕЛЯ ДЛЯ ЛУЧЕВОЙ ТЕРАПИИ ПОД ...

Gel formulations for guiding radiotherapy

본 발명은 국부 투약을 위한 X-선 대조 조성물을 서술하며, 여기서 X-선 대조 조성물은 대조 성질을 보여주고 X-선 대조 조성물을 사람 또는 동물의 신체에 투약한 경우 상기 X-선 대조 조성물의 투약량의 적어도60%가 24시간을 초과하여 주사위치에서 10cm내에 남아있다.

Polymeric therapeutic composition

Compositions for imaging of the gastrointestinal tract

The invention relates to non-ionic triiodo aromatic compounds and compositions comprising triiodo aromatic polymers useful for X-ray imaging of gastro-intestinal tract. Disclosed compounds are acrylic acid esters of triiodobenzenes with a different degree of reticulation and their polymers/homopolymers. A method of making the polymers, method of making X-ray contrast agents using the polymers and use of the contrast agents is also disclosed.

Polymers

The invention provides compounds comprising a linear, branched or dendrimeric polymer backbone with linked thereto at least one reporter moiety, said polymer backbone comprising a plurality of amine-containing acids. Such compounds may be linked to one or more targeting agents and are useful as therapeutic and diagnostic agents, in particular in medical imaging techniques.

Composotions and methods for radiographic imaging

A radiographic imaging agent including a plurality of block copolymers forming a micelle, the block copolymers including a hydrophilic polymer linked to a hydrophobic polymer, and the hydrophobic polymer including a backbone incorporating radiopaque molecules via covalent bonds.

Radio-opaque polymeric compositions

The present invention provides a radio-opaque composition including a polymer or monomer, wherein the polymer or monomer has a non-leachable radio-opaque moiety. The non-leachable radio-opaque moiety is covalently attached to the polymer or monomer.

IODINE POLYMERS, THEIR PREPARATION PROCESSES AND THEIR APPLICATIONS AS CONTRAST PRODUCTS

IODINE POLYMERS WITH DEXTRAN SKELETON, METHODS OF PREPARING THEM AND APPLICATIONS THEREOF AS CONTRAST PRODUCTS

Embolic prosthesis for treatment of vascular aneurysm

The invention relates to an implantable embolic medical device comprising a non-erodible, erodible or biodegradable material. The device preferably comprises one or more longitudinal filament members of varying cross sectional shapes which may or may not be coiled to suit a particular clinical need. The embolic device is placed through lumens and cavities to reach areas in the body which require embolism to achieve a particular clinical objective.

METAL COMPLEXES OF POLYAMINOACIDS, THEIR PREPARATION PROCESS AND THEIR USE IN DIAGNOSTIC IMAGING

Radiopaque shape memory polymers for medical devices

Radiopaque polymer compositions and methods for making the compositions are provided. These radiopaque polymer compositions include shape memory polymer compositions comprising a crosslinked polymer network, the network comprising a first repeating unit derived from a monofunctional iodinated monomer and a second repeating unit derived from a multifunctional non-iodinated monomer wherein neither of the two monomers is fluorinated. Devices formed from radiopaque polymer compositions are also provided.

New iodine-containing polyamino macromolecular compound, process for its preparation and its use as contrast agent

Polyamino macromolecular compound of biological or synthetic origin, characterised in that it carries at least three iodine-containing radioopaque derivatives.

Liquid embolic compositions and uses thereof for treating vascular conditions

Polymeric compositions are described comprising a biocompatible polymer including a biodegradable linkage to a visualization agent and a non-physiological pH solution; wherein the biocompatible polymer is soluble in the non-physiological pH solution and insoluble at a physiological pH. Methods of forming the solutions and polymers are disclosed as well as methods of therapeutic use.

Composition for imaging of gastrointestinal tract comprising triiodobenzene polymer

Embolic prosthesis for treatment of vascular aneurysm

POLYMERIC TREATMENT COMPOSITIONS

COMPOSIÇÕES POLIMÉRICAS DE TRATAMENTO. Descrevem-se composições poliméricas que compreendem: um polímero biocompatível que inclui uma ligação biodegradável a um agente de visualização, e uma solução não-fisiológica; na qual o polímero biocompatível é solúvel em solução de pH não fisiológico e insolúvel em pH fisiológico. Métodos de formação de soluções e polímeros são revelados, bem como métodos de utilização terapêutica. POLYMERIC TREATMENT COMPOSITIONS. Polymer compositions are described which comprise: a biocompatible polymer which includes a biodegradable bond to a visualization agent, and a non-physiological solution; in which the biocompatible polymer is soluble in solution at non-physiological pH and insoluble at physiological pH. Methods of forming solutions and polymers are disclosed, as well as methods of therapeutic use.

IODATED POLYMERS AND PROCEDURES FOR PREPARING THEM AND THEIR USE AS CONTRACTING AGENTS

Animal model for detection of vulnerable plaques

The present invention provides in vivo methods for detection of vulnerable plaque in a subject in need thereof. In the invention method the subject is administered a diagnostic amount of a biologically compatible detectable lipid-avid agent, the detectable lipid-avid agent is allowed to penetrate arterial walls and attach to any lipid accumulations of oxidized LDL-cholesterol in arterial walls in the wall of an artery; unbound detectable lipid-avid agent is allowed to clear from the body by natural processes, and the presence of the detectable lipid-avid agent attached to the lipid accumulation in the wall of the artery is detected. Detection of bound lipid-avid agent indicates the presence of a vulnerable plaque and predicts a heightened risk of lethal heart attack or thrombus. The detectable lipid-avid agent is selected for its ability to penetrate arterial walls and bind with oxidized LDL-cholesterol in the lipid accumulation in a vulnerable plaque. Alternatively, macrophage-avid agents, for example a lipid-avid agent attached to a macrophage-specific antibody, can be used in the invention methods. The invention further includes methods for in vitro assays for detecting vulnerable plaque and a porcine animal model of vulnerable plaque useful for testing treatment modalities.

Biocompatible iodinated diphenol monomers and polymers

Polyiodinated compounds, their preparation and their use as contrast media for radiology

The present invention relates to polyiodinated compounds with a single molecular weight having a molecular concentration of iodine of greater than approximately 20% by weight, and in particular greater than approximately 30% by weight, containing at least 9 iodine atoms and having a molecular weight above 2000 and below approximately 50,000, and in particular above 2000 and below approximately 20,000, said compounds possessing either a zero overall electrical charge or at least two anionic charges, and persisting in the vascular compartment at a value equal to at least approximately 30% by weight of the injected dose in a subject five minutes after intravascular administration in the said subject.

Compositions for nanoconfinement induced contrast enhancement and methods of making and using thereof

Multivalent CT or MR contrast agents and methods of making and using thereof are described herein. The agents contain a moiety, such as a polymer, that provides multivalent attachment of CT or MR contrast agents. Examples include, but are not limited to, multivalent linear polymers, branched polymers, or hyperbranched polymers, such as dendrimers, and combinations thereof. The dendrimer is functionalized with one or more high Z-elements, such as iodine. The high Z-elements can be covalently or non-covalently bound to the dendrimer. The dendrimers are confined in order to enhance CT contrast. In some embodiments, the moiety is confined by encapsulating the dendrimers in a material to form particles, such as nanoparticles. In other embodiments, the dendrimer is confined by conjugating the moiety to a material, such as a polymer, which forms a gel upon contact with bodily fluids.

Imageable embolic microsphere

This invention concerns imageable, radiopaque embolic beads, which are particularly useful for monitoring embolization procedures. The beads comprise iodine containing compounds which are covalently incorporated into the polymer network of a preformed hydrogel bead. The beads are prepared by activating pre-formed hydrogel beads towards nucleophilic attack and then covalently attaching iodinated compounds into the polymer network. The radiopaque beads may be loaded with chemotherapeutic agents and used in methods of embolizing hyperplastic tissue or solid tumors.

IODINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS CONTRACTORS IN RADIOLOGY X.

DERIVADOS POLIYODADOS DE FORMULA (I), EN LA QUE A ES UN RESTO DE UNA MOLECULA AROMATICA O ALIFATICA, ZA, ZB, ZC, ZD REPRESENTAN TZ-QZ-VZ, PUDIENDO TZ Y VZ SER O, COND, O NDCO, PUDIENDO D SER H, ALQUILO O HIDROXIALQUILO TENIENDO DE 1 A 6 ATOMOS DE CARBONO Y QZ ALQUILENO O HIDROXIALQUILENO TENIENDO DE 1 A 6 ATOMOS DE CARBONO O TENIENDO VZ LA SIGNIFICACION ANTERIOR O QZ Y/O TZ NO EXISTEN, XA, XB, XC, XD, IDENTICOS O DIFERENTES REPRESENTAN (II) EN LA QUE AR Y AR'' SON GRUPOS FENILOS TRI O TETRAYODADOS Y QUE LLEVAN UNO O DOS GRUPOS AMIDAS SUSTITUIDAS POR ALQUILOS, EVENTUALMENTE HIDROXILADOS, Y LOS T, Q, V TIENEN UNA DE LAS SIGNIFICACIONES DE LOS TZ, QZ, VZ O LOS X REPRESENTAN (II''), EN LA QUE AP Y A''P REPRESENTAN LA FORMULA (II) ANTERIOR Y LOS T, Q, V TIENEN UNA DE LAS SIGNIFICACIONES DE LOS TZ, QZ, VZ. APLICACION DE ESTOS PRODUCTOS COMO AGENTES DE CONTRASTE PARA LA RADIOLOGIA POR RAYOS X. POLYYODATED DERIVATIVES OF FORMULA (I), IN WHICH A IS A REST OF AN AROMATIC OR ALIPHATIC MOLECULA, ZA, ZB, ZC, ZD REPRESENT TZ-QZ-VZ, PUDIENDO TZ AND VZ SER O, COND, O NDCO, PUDIENDO D SER H, ALKYL OR HYDROXIALKYL HAVING 1 TO 6 CARBON ATOMS AND QZ ALKYLENE OR HYDROXYALKYLENE HAVING 1 TO 6 CARBON ATOMS OR HAVING VZ THE PREVIOUS SIGNIFICANCE OR QZ AND / OR TZ DO NOT EXIST, X, X IDENTICAL OR DIFFERENT REPRESENT (II) IN WHICH AR AND AR '' ARE TRI PHENYLIC GROUPS OR TETRAYODADOS AND THAT CARRY ONE OR TWO AMIDAS GROUPS REPLACED BY RENT, EVENTUALLY HYDROXYLATED, AND THE T, Q, V HAVE ONE OF THE MEANINGS TZ, QZ, VZ OR THE X REPRESENT (II ''), IN WHICH AP AND A``P REPRESENT THE PREVIOUS FORMULA (II) AND THE T, Q, V HAVE ONE OF THE MEANINGS OF THE TZ, QZ, VZ . APPLICATION OF THESE PRODUCTS AS CONTRACT AGENTS FOR X-RAY RADIOLOGY.

Activity based probe and uses thereof for imaging

New core and core-shell nanoparticles containing iodine for x-ray imaging

Nanoparticles having an average particle size of less than 2000nm, wherein said nanoparticles comprise a polymer having pendant cleavable iodine substituted groups are provided. Processes for preparing the nanoparticles and their use as a contrast agent for X-ray imaging are also described.

Metal complexes of polyaminoacids, and their utilization in diagnostic imaging

The invention relates to complexes of gadolinium having the formula (I) wherein R is a group having formula (1). These complexes are usable in the field of diagnostic imaging.

Radiopaque polymers with enhanced radiopacity

Radiopaque polymer compositions and methods for making the compositions are provided. These radiopaque polymer compositions include polymer compositions comprising a crosslinked polymer network, the network comprising a first repeating unit derived from a monofunctional monomer, a second repeating unit derived from a crosslinker monomer having more than two polymerizable groups and a third repeating unit a derived from a crosslinker monomer having two or more polymerizable groups. Devices formed from radiopaque polymer compositions and methods for synthesizing radiopaque polymer compositions are also provided.

Imageable polymers

This invention relates to imageable polymers, particularly those comprising poly vinylalcohol and to methods for making them as well as to embolic microspheres comprising the polymers. The microspheres are imageable during embolization procedures and can be loaded with drugs or other therapeutic agents to provide an imageable drug delivery system.